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Abstract 
 
The discovery of peptide-based targeted imaging agents is hindered by the required 
addition of a radionuclide that can affect the binding properties of the peptide.  Screening 
of peptide libraries is problematic because they do not take into account the presence of 
the imaging agent.  Herein the development of an organometallic OBOC peptide library 
that contain a rhenium(I) tricarbonyl-based imaging entity surrogate incorporated directly 
onto the peptide chain, is reported.  Additionally, MALDI tandem mass spectrometry is 
reported as a method to deconvolute organometallic peptides containing four different 
rhenium(I) tricarbonyl chelates on the N-terminus of octapeptides.  Furthermore, an 
organometallic OBOC peptide library is created and screened against the GLP-1R 
(glucagon-like peptide 1 receptor) in order to discover potential imaging agents for 
diagnosis of diabetes and insulinomas.  The methods reported herein can be applied to 
develop peptide-based imaging agents for a wide variety of relevant targets. 
 
Keywords:  Molecular Imaging, OBOC library, Rhenium(I) tricarbonyl, Peptide 
fragmentation, MALDI, GLP-1R 
  
 
 
iv 
 
Statement of Co-Authorship 
 
Chapter 2:  All work in this chapter was completed solely by the author 
Chapter 3:  All work in this chapter was completed by the author with the exception of 
MALDI tandem mass spectrometry data acquisition.  This was done by Dr. Christina 
Booker and Ms. Kristina Jurcic of the UWO MALDI MS Facility under the supervision 
of Dr. Ken Yeung, an associate professor at the University of Western Ontario jointly 
appointed to the Departments of Chemistry and Biochemistry. 
Chapter 4:  The creation of fluorescent CHO GLP-1R and CHO cells was done by the 
laboratory of Dr. Savita Dhanvantari, an assistant professor in Medical Biophysics at the 
University of Western Ontario.  The work was done by Ms. Rebecca McGirr, a technician 
in the lab.  Bead incubation was also done with their assistance. 
  
 
 
v 
 
Acknowledgements 
 
 I would like to thank everyone who supported me throughout graduate studies 
over the past two years. 
 Special thanks to Dr. Len Luyt, a great supervisor, who was always available to 
help, guide and advise me through my time in the lab.   
I would like to thank Dr. Ken Yeung, and especially Dr. Christina Booker and 
Ms. Kristina Jurcic, members of his lab, for consistently providing timely access to mass 
spectrometry facilities as well as advice.  Also, thanks to Dr. Savita Dhanvantari and Ms. 
Rebecca McGirr for their time and biological expertise. 
Special thanks to all of the students and postdocs, past and present, in the Luyt 
Lab.  Their aid and knowledge helped me greatly in completing my research, as well as 
always making it a great environment to work. 
Also, thanks to my family and friends who probably had to endure too much 
“chemistry talk” over the course of my university studies; I couldn’t have done it without 
you. 
  
 
 
vi 
 
Table of Contents 
CERTIFICATE OF EXAMINATION .......................................................................... II 
ABSTRACT ..................................................................................................................... III 
STATEMENT OF CO-AUTHORSHIP ........................................................................ IV 
ACKNOWLEDGEMENTS ............................................................................................. V 
LIST OF TABLES .......................................................................................................... IX 
LIST OF FIGURES ........................................................................................................ XI 
LIST OF SCHEMES ..................................................................................................... XV 
LIST OF ABBREVIATIONS .................................................................................... XVII 
CHAPTER 1:  INTRODUCTION .................................................................................... 1 
1.1 MOLECULAR IMAGING ................................................................................................ 1 
1.2  PET AND SPECT MOLECULAR IMAGING AGENTS..................................................... 3 
1.3  PEPTIDES AS TARGETING ENTITIES ............................................................................ 6 
1.4  DISCOVERY AND DEVELOPMENT OF PEPTIDE-BASED IMAGING AGENTS .................... 9 
1.5  DECONVOLUTION AND IDENTIFICATION OF PEPTIDE SEQUENCES ............................ 17 
1.6  ORGANOMETALLIC OBOC PEPTIDE LIBRARIES ....................................................... 19 
1.7  THESIS SCOPE .......................................................................................................... 22 
CHAPTER 2:  SYNTHESIS OF RHENIUM(I) TRICARBONYL CHELATES 
AS IMAGING ENTITY SURROGATES ...................................................................... 24 
2.1 INTRODUCTION ......................................................................................................... 24 
2.1.2 Development of Rhenium/Technetium(I) Tricarbonyl Cores .......................... 25 
2.1.3 The Properties of Rhenium(I) Tricarbonyl Complexes .................................... 26 
2.2 RESULTS AND DISCUSSION ....................................................................................... 28 
2.2.1 2-Picolylamino-N,N-Diacetic Acid (N,N,O) Rhenium(I) Tricarbonyl 
Chelate ....................................................................................................................... 30 
2.2.2 Bispicolylamino Acetic Acid (N,N,N) Rhenium(I) Tricarbonyl Chelate......... 34 
2.2.3 Nitrilotriacetic Acid (N,O,O) Rhenium(I) Tricarbonyl Chelate ....................... 36 
2.2.4 2-Picolylamino-N,N-2-Hydroxybenzyl Acetic Acid (N,N,O) Rhenium(I) 
Tricarbonyl Chelate ................................................................................................... 37 
2.3 CONCLUSIONS .......................................................................................................... 42 
2.4 EXPERIMENTAL ........................................................................................................ 42 
2.4.1 General Procedures ........................................................................................... 42 
2.4.2 Small Molecule Synthesis ................................................................................ 43 
CHAPTER 3:  INVESTIGATION INTO THE FRAGMENTATION OF 
ORGANOMETALLIC PEPTIDES ............................................................................... 52 
 
 
vii 
 
3.1 INTRODUCTION ......................................................................................................... 52 
3.1.1 Peptide Synthesis .............................................................................................. 52 
3.1.2 Mass Spectrometric OBOC Sequencing Methods ............................................ 54 
3.1.3 Tandem Mass Spectrometry and Peptide Fragmentation ................................. 58 
3.2 RESULTS AND DISCUSSION ....................................................................................... 62 
3.2.1 Organometallic Peptide Synthesis .................................................................... 62 
3.2.2 MALDI Tandem Mass Spectrometry ............................................................... 67 
3.3 CONCLUSIONS .......................................................................................................... 77 
3.4 EXPERIMENTAL ........................................................................................................ 78 
3.4.1 General procedures and materials ..................................................................... 78 
3.4.2 General Peptide Synthesis ................................................................................ 79 
3.4.3 Organometallic Coupling Procedure ................................................................ 80 
3.4.4 Peptide Deprotection, Cleavage and Purification ............................................. 81 
3.4.5 MALDI Tandem Mass Spectrometry ............................................................... 83 
CHAPTER 4:  THE SYNTHESIS AND SCREENING OF 
ORGANOMETALLIC OBOC PEPTIDE LIBRARIES .............................................. 84 
4.1 INTRODUCTION ......................................................................................................... 84 
4.1.1 OBOC Libraries ................................................................................................ 84 
4.1.2 Glucagon-Like Peptide 1 Receptor ................................................................... 87 
4.2 RESULTS AND DISCUSSION ....................................................................................... 92 
4.2.1 Single bead MALDI Tandem Mass Spectrometry ........................................... 92 
4.2.2 Organometallic OBOC Peptide Library Synthesis ........................................... 96 
4.2.3 Single Bead Organometallic OBOC Peptide Deconvolution ........................... 97 
4.2.4 Organometallic OBOC Peptide Library Screening Against the GLP-1R ........ 99 
4.2.5 MALDI TOF/TOF Deconvolution of “Hit” Library Beads ........................... 105 
4.3 CONCLUSIONS ........................................................................................................ 110 
4.4 EXPERIMENTAL ...................................................................................................... 111 
4.4.1 General Procedures ......................................................................................... 111 
4.4.2 Single Bead Organometallic Peptide Synthesis .............................................. 112 
4.4.3 OBOC Library Synthesis ................................................................................ 113 
4.4.4 Cell Growth .................................................................................................... 114 
4.4.5 Library Incubation .......................................................................................... 114 
4.4.6 Library Screening ........................................................................................... 114 
4.4.7 MALDI Tandem Mass Spectrometry ............................................................. 115 
CHAPTER 5:  CONCLUSIONS .................................................................................. 116 
CHAPTER 6:  REFERENCES ..................................................................................... 120 
APPENDIX I – CHAPTER 2 ........................................................................................ 129 
APPENDIX II – CHAPTER 3 ...................................................................................... 142 
 
 
viii 
 
APENDIX III – CHAPTER 4 ....................................................................................... 146 
CIRRICULUM VITAE ................................................................................................. 153 
 
  
 
 
ix 
 
List of Tables 
 
Table 1.1  Common positron emitting radionuclides for PET, showing their half-life 
and method of production.
6
 .................................................................................................. 5 
 
Table 1.2  Common gamma ray emitting radionuclides for SPECT, showing their 
half-life and method of production.
7
 .................................................................................... 5 
 
Table 3.1  Fragment assignments from series b and y of the product ion spectrum of 
compound 3.2.  [M+H]
+ 
m/z = 1430.5 (rhenium-185 peak) .............................................. 70 
 
Table 3.2  Fragment assignments from series b and y of the product ion spectrum of 
compound 3.4.  The masses of the b8 and y8 ions can be determined because of the 
known mass of the peptide and the N-terminal chelate.  [M+H]
+ 
m/z = 1397.5 
(rhenium-185 peak). ........................................................................................................... 72 
 
Table 3.3  Fragment assignments from series b and a of the product ion spectrum of 
compound 3.3.  The masses of the b8 and a8 ions can be determined because of the 
known mass of the peptide.  The relationship between the a and b series is the loss of 
a carbonyl, m/z = 28.  [M]
+ 
m/z = 1463.6 (rhenium-185 peak). ......................................... 74 
 
Table 3.4  Fragment assignments from series b of the product ion spectrum of 
compound 3.6.  The masses of the b8 ion can be determined because of the known 
mass of the peptide.  [M+H]
+ 
m/z = 1478.5 (rhenium-185 peak). ..................................... 75 
 
Table 3.5  The observed fragments in the product ion spectrum of compound 3.6 due 
to the loss of an m/z = 106 corresponding to the loss of an ortho quinone methide. ......... 77 
 
Table 4.1  Deconvoluted PADA-Re(CO)3 peptides from an organometallic OBOC 
peptide library sequenced through manual de novo methods. ........................................... 98 
 
Table 4.2  Fragment assignments from series b of the product ion spectrum of 
compound 4.8.  The masses of the b8 ion can be determined because of the known 
mass of the peptide and the N-terminal chelate.  [M+H]
+ 
m/z = 1497.52 (rhenium-185 
peak). ................................................................................................................................ 107 
 
 
 
x 
 
Table 4.3  Fragment assignments from series b and y of the product ion spectrum of 
compound 4.9.  The masses of the b8 ion can be determined because of the known 
mass of the peptide and the N-terminal chelate.  [M+H]
+ 
m/z = 1353.48 (rhenium-185 
peak). ................................................................................................................................ 109 
  
 
 
xi 
 
List of Figures 
 
Figure 1.1  a)  
18
F-fluorodeoxyglucose, a widely used analogue of glucose used often 
to image tumors due to either high uptake of sugars.  b)  Tc-MIBI, a non-specific 
imaging agent used especially for cardiac imaging. ............................................................ 3 
 
Figure 1.2  The general formulation of a targeted imaging agent, including a 
targeting entity, responsible for interactions with specific receptors, an imaging 
entity necessary for visualization and a linker sometimes included minimize 
interference between the two entities. ................................................................................. 4 
 
Figure 1.3  A peptide-based imaging agent containing a D-Phe and D-Trp, 
octreotide, acting on the somatostatin receptor.  The peptide is cyclised via a 
disulfide bond and contains the imaging entity 
111
In-DTPA 
(diethylenetriaminepentaacetic acid). ................................................................................. 8 
 
Figure 1.4   Flow chart of the available methods for developing imaging agents ............. 9 
 
Figure 1.5  Overview of the methodology associated with utilizing phage display 
libraries for discovering peptide-protein interactions. ...................................................... 14 
 
Figure 1.6  The synthesis of OBOC peptide libraries, where A-E are amino acids, 
using two mix-split steps.  The number of possible peptide sequences increases 
exponentially with each step, following the formula N = p
a
, where N is the number of 
sequences, p is the number of amino acids in a peptide, and a is the number of amino 
acids available. .................................................................................................................. 15 
 
Figure 1.7  5-iodobenzovesamicol and the compound with a technetium chelate.  
The addition of the imaging moiety decreases binding affinity by over 100 fold. ........... 19 
 
Figure 2.1  Partial molecular orbital diagrams for octahedral complexes of 
rhenium(I).  The first diagram shows the splitting associated with ligands which do 
not accept or donate π electrons.  The second diagram illustrates the increase in Δoct 
associated with having ligands which accept electron density, as is the case with 
carbonyl ligands.  This occurs because the symmetry of the π* orbitals and three of 
the d orbitals of the rhenium are identical......................................................................... 27 
 
 
 
 
xii 
 
 
Figure 2.2  
1
H NMR spectrum showing the AB spin systems associated with the 
formation of a stereogenic centre upon Re(CO)3
+
 coordination of the PADA ligand, 
compound 2.7.  Each AB spin system represents two methylene protons, each in a 
different chemical environment... ..................................................................................... 33 
 
Figure 2.3  Phenol based (N,N,O) coordination of rhenium(I) tricarbonyl.  R = H, -
CH2CH=CH2, -(CH2)2CN.  In these complexes, amines are shown to preferentially 
donate electrons to the rhenium(I) tricarbonyl in comparison to the phenol ligand ......... 38 
 
Figure 2.4  
1
H NMR spectrum of 2.12a showing the region from approximately 6 
ppm to 11 ppm in CDCl3.  The appropriate aromatic peaks are visible along with a 
peak at 10.3 ppm corresponding to the phenol proton ..................................................... .39 
 
Figure 2.5  A comparison of the 
1
H NMR spectra obtained from A) un-coordinated 
compound 2.13, and B)  coordinated compound 2.14, in deuterated methanol.  All of 
the aromatic peaks shift downfield as a result of the addition of the rhenium(I) 
tricarbonyl.  ....................................................................................................................... 40 
 
Figure 3.1  The general procedure of peptide deconvolution through the use of 
ladder synthesis and partial Edman degradation coupled with mass spectrometry .......... 56 
 
Figure 3.2  The utilization of linear peptides to code for bioactive cyclic peptides on 
a single bead.  The inner core of the bead holds the tagging linear peptide and can be 
sequenced by MS methods in order to identify the cyclic tripeptide. ............................... 57 
 
Figure 3.3  A generic tetrapeptide holding a positive charge on the N-terminus.  This 
compound is fragmented through CID to produce one of the fragments.  The a2 and 
b2 fragments are N-terminal fragments while the x2 and y2 fragments are C-terminal. .... 59 
 
Figure 3.4  Crude HPLC UV trace of Re(CO)3-NTA-QATDKFTF-NH2 (3.4) after 
cleavage from resin.  The major peak at 9.90 min represents the desired product with 
an m/z 1399.  The two peaks at 3.91 and 5.58 min show an observed mass of m/z 956 
and 1129 which correspond to the H-QATDKFTF-NH2 and NTA-QATDKFTF-NH2, 
respectively. ...................................................................................................................... 66 
 
Figure 3.5  MALDI MS precursor ion spectrum for 3.2.  The organometallic peptide 
has the expected rhenium 185/187 isotope ratio.  [M+H]
+
 m/z calc: 1432.49 obs: 
1432.50 .............................................................................................................................. 68 
 
 
 
xiii 
 
Figure 3.6  The product ion spectrum of compound 3.2.  The corresponding 
assignments of b and y series can be seen at the top of the figure.  The identity of 
amino acids is determined based on the difference between the m/z in two adjacent 
peaks of the same series. ................................................................................................... 69 
 
Figure 3.7  Two adjacent peaks, b4 and b5, from the product ion spectrum of 
compound 3.2.  The rhenium isotopic ratio can clearly be seen in each of the peaks, 
verifying the assignment of their identities as N-terminal fragments. .............................. 70 
 
Figure 3.8  The product ion spectra of compounds 3.2, 3.3, 3.4 and 3.6.  The effects 
of different rhenium(I) tricarbonyl chelates can be seen in the fragmentation patterns 
and intensities of each spectra. .......................................................................................... 71 
 
Figure 4.1  An example of the peptide-like compounds created in OBOC libraries by 
Aditya et al.  These compounds are similar to peptides in structure, however they are 
expected to have long biological half-lives.  These compounds were sequencing by 
MALDI TOF/TOF. ........................................................................................................... 86 
 
Figure 4.2  Allosteric small molecule antagonists of the GLP-1R. ................................. 91 
 
Figure 4.3  A comparison of the product ion spectra of compound 3.2 obtained by 
MALDI TOF/TOF mass spectrometry.  a)  The spectrum is the purified 
organometallic peptide.  b) The spectrum of the organometallic peptide cleaved from 
a single 90 µm tentagel bead under OBOC screening conditions.  The spectra are 
very similar and contain identical peaks. .......................................................................... 95 
 
Figure 4.4  The procedure for screen an OBOC peptide library against cells.  This 
technique accounts for non-specific binding interactions. .............................................. 100 
 
Figure 4.5  Organometallic OBOC peptide library after incubation with GFP 
expressing cells.  There are a number of beads circled in white that show interaction 
with the cells while most do not.  The intensity of the auto-fluorescence of the 
tentagel beads varies from bead to bead. ........................................................................ 101 
 
Figure 4.6  A diagram of CHO cells showing green and red fluorescence.  The green 
cells express GFP (green fluorescent protein) and act a control for non-specific 
binding.  The red cells express tdTomato and overexpress the GLP-1R. ....................... 102 
 
 
 
 
xiv 
 
Figure 4.7  A graph from the COPAS biosorter showing two distinct populations of 
beads after incubation with green control cells.  The y-axis is a measurement of green 
fluorescence and the x-axis is the time-of-flight or size.  The top population shows 
increased fluorescence and contains GFP CHO cells with non-specific binding 
interactions.  The bottom population contains no cells. .................................................. 103 
 
Figure 4.8  Tentagel bead interacting with three visible GFP expressing cells. ............ 104 
 
Figure 4.9  A graph from the COPAS biosorter with the y-axis is a measurement of 
red fluorescence and the x-axis is time-of-flight or size.  This graph illustrates that 
there are not two distinct populations of beads containing red cells and those without. 105 
 
Figure 4.10  The product ion spectrum of the organometallic octapeptide 4.8 
showing the b series fragments. ...................................................................................... 106 
 
Figure 4.11  The product ion spectrum of the organometallic octapeptide 4.9 
showing the b series fragments. ...................................................................................... 108 
 
  
 
 
xv 
 
List of Schemes 
 
Scheme 1.1  Edman degradation utilizing phenylisothiocyanate to form a 
phenylthiohydantoin derivative.......................................................................................... 17 
 
Scheme 2.1  The synthesis of rhenium(I) tricarbonyl staring materials.  Compound 
2.1 contains three labile bromide ligands which can be easily substituted as well as 
two tetraethylammonium counterions.  Comparatively, 2.2 contains three labile aqua 
ligands and exists in an aqueous solution with a triflate counterion. ................................. 29 
 
Scheme 2.2  Synthesis of Re(CO)3-PADA.  Reagents:  a) Ethylbromoacetate, NEt3, 
DMF, 0
o
C.  b)  KOH, EtOH, 0
o
C.  c)  2.1, MeOH ............................................................ 30 
 
Scheme 2.3  Synthesis of PADA (2.6).  Reagents:  a)  KOH, MeOH, reflux 24 h. .......... 32 
 
Scheme 2.4  Synthesis of Re(CO)3-PADA (2.7).  Reagents:  a)  MeOH, 2.1 .................. 32 
 
Scheme 2.5  Synthesis of BPA (2.8).  Reagnets:  a)  NaOH, MeOH, reflux 24 h. ........... 34 
 
Scheme 2.6  Synthesis of Re(CO)3-BPA (2.9).  Reagents:  a)  2.1, MeOH, reflux........... 35 
 
Scheme 2.7  Synthesis of Re(CO)3-NTA (2.10).  Reagents:  a) NaOH(aq), 2.2 ................. 36 
 
Scheme 2.8  Synthesis of PHA (2.13) and Re(CO)3-PHA (2.14).  Reagents:  a) 1. 
MeOH 2. NaBH4.  b) tert-butyl, benzyl, ethyl bromoacetate or benzyl bromoacetate, 
NEt3, MeCN.  c) 2.12a, TFA, DCM.  d) 2.2, H2O, NaOH. ............................................... 38 
 
Scheme 3.1  A diagram of the removal of an Fmoc group and the addition of a 
second amino acid to a resin bound amino acid.  This process is repeated until the 
desirable peptide is synthesized. ........................................................................................ 53 
 
Scheme 3.2  Synthesis of organometallic peptides.  Reagents:  a)  20% piperidine in 
DMF  b)  HBTU, DIPEA, rhenium(I) tricarbonyl chelate in DMF.  Rhenium(I) 
tricarbonyl chelates 2.7, 2.9 and 2.10 were coupled onto the N-terminus of 3.1 to 
produce 3.2, 3.3 and 3.4, respectively. ............................................................................... 63 
 
Scheme 3.3  A potential reaction during the activation of the carboxylate of 2.13 
with the coupling reagent HBTU.  The phenol nucleophile might be expected to form 
a seven membered cylic ring system through intramolecular nucleophylic acyl 
substitution of the activated ester. ...................................................................................... 64 
 
 
xvi 
 
Scheme 3.4  Synthesis of 3.6.  Reagents:  a)  20% piperidine in DMF.  b)  HBTU, 
DIPEA, 2.13 in DMF.  c)  [Et4N]2[Re(CO)3Br3], DIPEA, in MeOH/DMF.  Synthesis 
of Re(CO)3-PHA-QATDKFTF (3.6) proceeds through on an on resin coordination 
methodology. ..................................................................................................................... 65 
 
Scheme 3.5  The proposed fragmentation mechanism of the phenol-based chelate in 
compound 3.6.  The creation of an ortho quinone methide accounts for the loss of m/z 
= 106 observed in the mass spectrum. ............................................................................... 76 
 
Scheme 4.1  The synthesis of compound 3.2 on tentagel S NH2 resin with a UV 
cleavable ANP photolinker.  The organometallic peptide was cleaved from a single 
bead. ................................................................................................................................... 93 
 
  
 
 
xvii 
 
List of Abbreviations 
 
AEEA 2-aminoethyoxy-2-ethoxyacetic acid 
ANP 2-amino-3-(2-nitrophenyl)propanoic acid 
Boc tert-butoxycarbonyl 
BPA Bispicolylamino Acetic Acid 
cAMP 
CID 
cyclic Adenosine monophosphate 
collision-induced dissociation 
CDCl3 deuterated chloroform 
CHCA trans-α-cyano-4-hydroxycinnamic acid 
CHO Chinese hamster ovarian 
DCM dichloromethane 
DIPEA diisoproylethylamine 
DMF dimethyl formamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTPA diethylenetriaminepentacetic acid 
EDTA ethylenediaminetetraacetic acid 
ESI electrospray ionization 
Et ethyl 
EtOAc ethyl acetate 
EtOH ethanol 
FDA U.S. Food and Drug Administration 
FDG fluorodeoxyglucose 
Fmoc fluorenylmethyloxycarbonyl 
GFP Green Fluorescent Protein 
GHSR-1 Growth Hormone Secretagogue Receptor 1 
GLP-1 Glucagon-Like Peptide 1 
GLP-1R Glucagon-Like Peptide 1 Receptor 
GLP-2 Glucagon-Like Peptide 2 
GPCR G protein coupled receptor 
HBSS Hank's buffered saline solution 
HBTU O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HCTU 2-(6-chloro-1H-benzotriazole-1-yl)- tetramethyl-uronium-hexafluoro-
phosphate 
HPLC high performance liquid chromatography 
IC50 half maximal inhibitory concentration 
MALDI matrix assisted laser desorption/ionization 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
MIBI methyoxyisobutyl iso cyanide 
MRI Magnetic Resonance Imaging 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
 
 
xviii 
 
Nic-OSu nicotinic acid hydroxysuccinimiydl ester 
NMR nuclear magnetic resonance 
NTA Nitrilotriacetic Acid 
OBOC one-bead, one-compound 
OTf trifluoromethanesulfonate 
PADA Picolylamino-N,N-Diacetic Acid 
PBS phosphate based buffer 
PED partial Edman degradation 
PEG polyethylene glycol 
PET Positron Emission Tomography 
PHA 2-Picolylamino-N,N-2-Hydroxybenzyl Acetic Acid 
QSAR quantitative structure-activity relationship 
RGD arginine-glycine-aspartic acid 
rpm revolutions per minute 
SN2 bimolecular nucleophilic substitution 
SPECT Single Photon Emission Computed Tomography 
tBu tert-butyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIS triisopropylsilane 
TOF time-of-flight 
TOF/TOF tandem time-of-flight 
UV ultraviolet 
 
 
1 
 
 
 
Chapter 1:  Introduction 
1.1 Molecular Imaging 
 
Molecular imaging allows for the non-invasive visualization of molecular 
pathways within the body.  It can be defined as the visualization, characterization and 
quantification of biological processes at the cellular and sub-cellular level.
1
  The use of 
molecular imaging has increasingly played a role in modern medicine because of the 
recognition of the importance of being able to detect, differentiate between, and treat 
diseases quickly and early in their development without using invasive procedures.  As a 
result, the development of molecular imaging techniques is an area of intensive research. 
There are a number of different molecular imaging modalities that find wide use 
in modern medicine such as MRI (magnetic resonance imaging), PET (positron emission 
tomography) and SPECT (single photon emission computed tomography).  The images 
from these modalities are often combined with each other, or techniques such as CT scans 
(x-ray computed tomography) to provide information about the presence, development, 
progress and potential treatment for a disease. 
PET and SPECT are both important molecular imaging techniques in nuclear 
medicine.  The general definition of nuclear medicine is the injection of radioactive 
substances (radiopharmaceuticals) into a biological system for diagnostic or therapeutic 
purposes.  More specifically, PET and SPECT rely on the introduction of radionuclides 
into the body and the subsequent detection of the radiation emitted.  If it can be shown 
that the radiopharmaceutical preferentially moves to a specific part of the body or type of 
2 
 
 
 
tissue, these techniques can provide a wealth of information about development and 
disease. 
While PET and SPECT imaging techniques both rely on radionuclides, there are a 
number of differences in the way in which radiation is detected.  PET relies on the ability 
of certain radionuclides, such as carbon-11, flourine-18 and gallium-68, to undergo beta 
decay resulting in the emission of a positron.  After a positron is emitted, it will move a 
very short distance until it comes into contact with an electron, which will result in an 
annihilation event.  This produces two gamma-rays at an angle of 180
o
 from one another.
2
  
These gamma rays are then detected by two cameras, and the information obtained is 
used to create an image. 
SPECT imaging detects gamma ray radiation emitted directly from radionuclides.  
This can occur by a number of mechanisms such as electron capture whereby a proton in 
the nucleus combines with an electron to form a neutron and a gamma ray.  This is the 
process which allows the use of iodine-123 and indium-111 for imaging purposes.  
However, radionuclides such as technetium-99m undergo gamma emission whereby a 
nucleus in a high energy state relaxes over time via the emission of a gamma ray.
3
  The 
electromagnetic radiation is then detected by a gamma camera and an image is formed. 
Because of the difference in radionuclides necessary for PET and SPECT, the use 
of either to diagnose or treat a specific disease is dependent on the discovery of suitable 
radiopharmaceutical probes, as well as the presence of necessary imaging equipment and 
the availability of specific radionuclides. 
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1.2  PET and SPECT Molecular Imaging Agents 
 
Despite the power of these two nuclear imaging techniques, the expanding use of 
SPECT and PET relies on the discovery and development of new radiopharmaceutical 
probes.  There are two broad classes of imaging agents:  targeted and non-targeted.  Non-
targeted imaging agents rely on general chemical properties such as size, charge and 
lipophilicity that determine the movement of the probe within the body.
3
  Many examples 
of these types of imaging agents are currently available and widespread in the clinic, such 
as the PET agent 
18
F-FDG (fluorodeoxyglucose), a glucose analogue which provides 
imaging based on sugar metabolism.
4
  An example of a SPECT non-targeted imaging 
probe for use in heart imaging that has found widespread use is 
99m
Tc-MIBI 
(methoxyisobutyl isocyanide).
5 
 The lipophilic cation proportionally distributes within the 
heart and allows for the effective imaging of blood flow. 
 
Figure 1.1  a)  
18
F-fluorodeoxyglucose, a widely used analogue of glucose used often to 
image tumors due to either high uptake of sugars.  b)  Tc-MIBI, a non-specific imaging 
agent used especially for cardiac imaging. 
 
Conversely, a targeted imaging probe usually contains two distinct parts (Figure 
1.2).  The first part is the imaging moiety, which for the purposes of SPECT and PET 
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must contain a radioactive isotope capable of emitting detectable radiation.  The imaging 
moiety is responsible for providing radiation in order to facilitate the visualization of the 
imaging agent’s location.  The second part is a targeting moiety which is responsible for 
the imaging agent’s distribution in a biological system, such as binding to a particular 
receptor or enzyme. 
 
Figure 1.2  The general formulation of a targeted imaging agent, including a targeting 
entity, responsible for interactions with specific receptors, an imaging entity necessary for 
visualization and a linker sometimes included minimize interference between the two 
entities. 
 
The number of useful imaging nuclei is a small fraction of the known radioactive 
elements due to a number of constraints necessary for medical use.  Imaging 
radionuclides must have a short enough half-life to emit enough detectable radiation 
within a reasonable time frame, as it would be inefficient and result in an unsafe radiation 
dose.  Further, the radionuclide must have a long enough half-life in order to be 
synthesized, incorporated into a probe and injected into an individual without significant 
decay.  For example, the most common medical radionuclide, technetium-99m emits 
detectable gamma rays with a half-life of approximately six hours.  Another example of a 
useful medical radionuclide is the positron emitting fluorine-18, which has a half life of 
approximately 110 minutes.  The different chemistry of radionuclides also plays an 
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important role in the development of imaging entities.  Radionuclides such as carbon-11 
and fluorine-18 can be incorporated directly into the structure of an imaging agent.  
Conversely, when utilizing metallic radionuclides such as technetium-99m and gallium-
68, a chelate must be formed in order for the metal to be incorporated into the 
radiopharmaceutical. 
Table 1.1  Common positron emitting radionuclides for PET, showing their half-life and 
method of production.
6
 
Isotope Half-life (min) Method of Synthesis 
11
Carbon 20.3 cyclotron 
13
Nitrogen 9.97 cyclotron 
15
Oxygen 2.03 cyclotron 
18
Fluorine 109.8 cyclotron 
64
Copper 768 cyclotron 
68
Gallium 67.7 generator 
82
Rubidium 1.26 generator 
 
Table 1.2  Common gamma ray emitting radionuclides for SPECT, showing their half-
life and method of production.
7
 
Isotope Half-life (hours) Method of Synthesis 
67
Gallium 78.3 cyclotron 
99m
Technetium 6 generator 
111
Indium 67.9 cyclotron 
123
Iodine 13.2 cyclotron 
201
Thallium 73.1 generator 
 
The second necessary part of an imaging probe is the targeting moiety.  The 
responsibility of the targeting moiety is to move the imaging moiety to a desired part of 
the biological system.  For example, a targeting moiety might be designed to move 
specifically to a particular type of cancer cell, such that when radiation is detected, it will 
reveal the location and size of tumors present throughout the body.  There are also a 
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number of necessary preconditions for a targeting entity to be useful in nuclear medicine.  
The targeting entity must have the ability to preferentially go to a desired part of the 
body.  The targeting entity must also be able to move quickly through the body to the 
area of interest, because of the time constraints imposed by using radionuclides.  
Additionally, the targeting moiety should not produce an immune response within the 
patient as well as being able to be cleared from the body after the imaging has been 
completed in order to minimize exposure to ionization radiation. 
Because of the necessary preconditions imposed upon a useful targeting entity, 
the development of molecular imaging agents relies heavily on the discovery and 
development of new targeting entities. 
 
1.3  Peptides as Targeting Entities 
 
Targeting entities can be composed from a diverse array of compounds such as 
small molecules, antibodies and peptides.  Small molecules, as a class of compounds, can 
be very useful targeting entities.  They are usually low molecular weight, which in theory 
gives them access to a very large number of targets in the body, both intracellular and 
extracellular receptors and enzymes.  In general, small molecules move quickly through 
the body and can be designed such that they have little trouble crossing biological 
barriers.  Further, there is a high level of diversity associated with small molecule 
targeting entities which allows a wide array of modifications in order improve 
performance.  In addition, small molecules are not readily degraded by enzymes in the 
body.  Small molecules are also generally feasible for rapid and efficient addition of 
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small radionuclides such as fluorine-18 and carbon-11.
8
  However, there are a number of 
drawbacks when investigating small molecules as targeting entities.  The discovery 
process for small molecule targeting agents is difficult and leads to few useable imaging 
agents.
9
  Additionally, because small molecules have low molecular weight, an 
acceptable imaging component rarely contains a metal radionuclide due to the overall 
mass and size of the chelate; this limits their use as targeted imaging agents. 
Another type of targeting moiety are antibodies; y-shaped proteins which are 
naturally produced by the body and utilized by the immune system.  They are very large 
(usually over 100 kDa) and bind to targets with extremely high affinity and specificity.  
They are also very stable to degradation in the body and relatively simple to synthesize 
biologically.  There are a number of FDA approved antibody-based imaging agents;
10
 
however as a class of compounds they suffer from a number of problems.  Because they 
are often recognized by the immune system of the target, a large number of undesired 
side effects are common, even in FDA approved radiopharmaceuticals.
11
  Further, 
because of their large size, they have difficulty reaching targets across biological barriers, 
thereby limiting their use.  Also, antibodies are not easily cleared from the body, possibly 
staying in the blood for weeks, resulting in poor image quality due to noise, and patients 
being exposed to high levels of unnecessary radiation.
12
 
Peptides are an important class of targeting entities because of a number of 
beneficial properties.   Peptides are larger than small molecules but still small in size 
when compared to antibodies.  Peptides can possess high selectivity for specific targets as 
well as access to a large number of relevant receptors, enzymes and proteins based on 
their ability to cross biological barriers.
13
  Peptides are also thought to be more useful 
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than small molecules in targeting enzymes or receptors which exhibit protein-protein 
interactions.  This because some protein-protein interactions occur over a wide surface 
area with no obvious binding pockets.
14
  These properties make peptides more promising 
imaging agents for these particular targets due to their ability to interact in a similar 
fashion.  Peptides are also a very diverse class of compounds, with the potential to use a 
large number of natural and unnatural amino acids, alter the chain length, utilize both L 
and D-amino acids and are easily modified.  When compared to antibodies, although 
peptides generally have lower affinity to targets, peptides rarely produce side effects
15
 
and have more favourable pharmacokinetic properties
16, 17
 resulting in higher quality 
images.  Also, peptides are more stable to the harsh chemical modification and 
radiolabelling conditions such as elevated temperatures or organic solvents.
18
  The 
beneficial properties of peptide-based imaging agents can be shown by the widespread 
use of Octreotide, an 
111
In-peptide imaging agent acting on the somatostatin receptor 
(Figure 1.3).
19
  Because of these advantages, peptides as targeting entities have become 
important in the development of novel molecular imaging agents. 
 
Figure 1.3  A peptide-based imaging agent containing a D-Phe and D-Trp, octreotide, 
acting on the somatostatin receptor.  The peptide is cyclised via a disulfide bond and 
contains the imaging entity 
111
In-DTPA (diethylenetriaminepentacetic acid). 
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1.4  Discovery and Development of Peptide-based Imaging Agents 
 
The development of suitable peptide-based molecular imaging agents can broadly 
be divided into two categories (Figure 1.4).  First, a rational design method can be taken.  
This approach relies on modifying peptide or peptide-like structures based on known 
information about the target.  Second, a random library approach may be taken.  In this 
method, one screens a large number of peptides (potentially millions) and determines 
which ligands show the most promise as imaging agents.  There are a number of 
advantages and disadvantages associated with both techniques. 
 
Figure 1.4   Flow chart of the available methods for developing imaging agents 
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Rational design has been a successful method in developing peptide-based 
therapeutic drugs.  There are a number of different tools available in the design of 
peptides, such as the truncation and modification of known biological peptides.  
Endogenous peptides are rarely useful imaging agents due to their short half-life in the 
body.  Rational modification of endogenous peptides can result in an increase in desired 
properties as well as maintenance of high selectivity and binding affinity.  Amino acids 
can be altered, D-amino acids can be added to increase biological half-lives, unnatural 
amino acids can be added and lipophilicity can be changed with careful modifications.  
This provides a wide array of potential tools available in the rational design process.  
Structural information can also be taken from the target of interest.  If the desired 
binding site is known, it is possible to construct a peptide based on the properties of the 
target itself.  Computational approaches to peptide-protein interaction using QSARs 
(quantitative structure-activity relationships) are useful, however the computational 
complexity of determining conformations of relatively large and flexible molecules with 
known protein structures has, despite steady advances in predictive ability, serious 
limitations.
20
  High resolution crystallographic information derived from target-ligand 
structures remains the most useful tool in designing peptide ligands as they can provide a 
wealth of information about specific binding interactions and conformations of the 
binding site.  Therefore, in utilizing a combination of the above approaches it is possible 
to design potential molecular imaging agents.  As an example of the rational design 
process, the endogenous peptide hormone ghrelin(1-28), a 28 amino acid peptide with an 
octanoylated side chain, binds to the growth hormone secretagogue receptor 1 (GHSR-
1),
21
 and is a promising candidate for prostate cancer imaging.  Rational modification of 
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this peptide chain has resulted in a significantly truncated amide peptide, ghrelin(1-
5)amide with effective maintenance of binding affinity.
22
  Additionally, modification of 
the octanoylated side chain with the radionuclides technetium-99m and fluorine-18
23
 has 
produced promising imaging agent candidates. 
However, there are a number of serious drawbacks in undertaking a rational 
design approach.  The entire rational design method relies on the availability of 
information about the specific target of interest.  If a rational design approach was to be 
undertaken to design a bioactive peptide sequence against a specific target, information 
about the endogenous ligand(s) and the binding site must already be known.  In many 
cases, there is not enough data on the desired target.  For example, obtaining crystal 
structures of protein active sites or protein-ligand interactions is a non-trivial exercise 
which results in few usable structures.  Further, of the structures available, comparatively 
few protein crystal structures are of high value therapeutic or diagnostic targets, as 
membrane bound proteins are particularly difficult and time-consuming to crystallize.
24
  
All rational design processes rely on prior knowledge about the system of interest in 
order to develop imaging agents, and in many cases this information is not readily 
available.  Because of this, other methods have been developed to aid in ligand discovery, 
in which a large precondition of target and ligand knowledge is not required. 
The use of peptide libraries strives to overcome the drawbacks associated with the 
rational design process.  In these methods, a large number of sequences are tested for 
binding affinity against a desired target.  The ligands that have shown high affinity to the 
target are identified and then can be further developed as imaging agents.  The advent of 
large scale economical automation has allowed these methods to become widely 
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available.  There are a number of benefits to this process.  First, the precondition of 
ligand and target information is dramatically lessened.  Second, in comparison to a 
rational design process, a large number of peptides which are potential imaging agents 
can be discovered and developed simultaneously for one target.  Third, the process is 
generally less time consuming than rational design, and potential peptides can be tested 
faster and more economically.  Fourth, because proteins usually contain many potential 
binding sites, the random library approach does not distinguish between sites.  As such, 
although subsequent tests might be necessary to determine where the peptides bind, this 
provides a particular advantage during imaging agent discovery because the peptide 
sequence is needed to locate the receptor, as opposed to induce or inhibit biological 
activity.  Furthermore, combinatorial approaches can be used in conjunction with the 
rational design process to aid in the discovery of new peptide ligands. 
Because of these benefits, a large variety of random libraries have been developed 
for the purpose of generating bioactive peptide ligands.  Generally, peptide libraries 
involve the synthesis of random sequences of amino acids on a solid support of some 
kind.  Random peptide libraries can further be divided in two categories, spatially and 
non-spatially addressable libraries.  Because the creation of peptide libraries inherently 
results in random peptide sequences, one of the main concerns with random libraries is 
determining the identity of a peptide with desired properties.   
In spatially addressable libraries, the identity of the peptide is known by its 
location on the solid support, such that if an interaction is observed, for example, at a 
particular spot on a peptide-coated plate, the location of the spot will allow determination 
of the peptide sequence.  Two such representative spatially addressable libraries are 
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SPOT and light directed libraries.  SPOT libraries were first reported by Frank in 1992
25
 
and utilize a cellulose solid support on which peptides are built.
26
  With automation, 
activated amino acids can be added sequentially to specific locations such that the 
identity of the peptide at that location is known.
27
  Light directed libraries created by 
Fodor et al. rely on a similar set of principles as SPOT libraries, by utilizing photomasks 
and photolabile protecting groups.
28
  Lasers are used to deprotect photolabile protecting 
groups at specific locations and activated amino acids are added.  When this process is 
repeated a number of times, many peptides can be built on the solid support and the 
identity of the peptides at each location will be known.  One of the main drawbacks 
associated with these types of libraries is there is a limit to the number of peptide 
sequences which can be screened at any given time.  Automation coupled with SPOT or 
light directed libraries can only result in tens of thousands of unique peptide sequences.
29
  
Although this is useful for small focused libraries in which only a few amino acids 
residues are altered while the others remain constant, large libraries containing perhaps 
millions of sequences are often required for drug or imaging agent discovery. 
Non-spatially addressable random peptide libraries are defined by the inability to 
identify the peptide sequence based on its location.  Two such examples of non-spatially 
addressable libraries are phage display libraries and OBOC (one-bead, one-compound) 
libraries.  Both of these libraries require further manipulation of the library in order to 
identify the bioactive peptide sequence.  However, it is possible to screen significantly 
more peptide sequences than in spatially addressable libraries, potentially numbering in 
the millions. 
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Phage display libraries are a broad classification of a type of biological library.  
The general process for creating phage display libraries (Figure 1.5) is as follows:  
phages, which are viruses infecting bacterial cells, are engineered with DNA coding for 
specific peptide sequences, which are then randomly mutated to create a large number of 
variations.  After infection of E. coli cells with these phages, the peptide sequences are 
synthesized as a coat protein for the phage.
30
  A phage display library has the potential to 
display billions of peptide sequences, of which bioactive peptides are identified based on 
DNA sequencing.  Moreover, phage display libraries can be used to investigate relatively 
large polypeptides in comparison to other synthetic methodologies.  Recently, 
Chakravarthy et al. utilized phage display libraries to discover a 174 amino acid 
polypeptide acting as an inhibitor to a protein kinase C enzyme,
31
 a class of proteins that 
are important pharmaceutical targets. 
 
Figure 1.5  Overview of the methodology associated with utilizing phage display 
libraries for discovering peptide-protein interactions. 
 
The problems associated with phage display libraries are mainly that there is a 
limitation to the types of peptides available to be tested.  During the process of 
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transcription and translation of DNA into peptides, the biological machinery recognizes 
specific DNA sequences which correspond to specific peptide sequences.  Because of 
this, the biological phage display library can only display peptides created from natural 
amino acids.  Peptides containing only natural amino acids are prone to quick degradation 
within the body and generally need to be modified with unnatural or D-amino acids.  
Despite these disadvantages, phage display libraries are popular because of their 
unparalleled diversity, commercial availability and speed at which bioactive peptide 
sequences can be obtained. 
OBOC libraries are another type of non-spatially addressable libraries.  Unlike 
phage display libraries, OBOC libraries are not biological in nature.  OBOC libraries 
involve the sequential synthesis of peptides on solid support beads.  This technique 
utilizes standard solid-phase peptide synthesis to build amino acid chains on beads 
composed of an insoluble backbone.    The creation of OBOC peptide libraries employs a 
split-mix methodology (Figure 1.6). 
 
Figure 1.6  The synthesis of OBOC peptide libraries, where A-E are amino acids, using 
two mix-split steps.  The number of possible peptide sequences increases exponentially 
with each step, following the formula N = p
a
, where N is the number of sequences, p is 
the number of amino acids in a peptide, and a is the number of amino acids available. 
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A group of single beads is split into a number of discrete wells, which correspond 
to the number of amino acids used.  The amino acids are then coupled to the beads.  
Subsequently, the beads from each well are then recombined and mixed together.  This 
mix-split cycle is then repeated as many times as necessary to produce the desired length 
of peptide.
32
  With every mix-split cycle, the number of possible sequences increases 
exponentially.  In this way, each bead will contain many copies of unique peptide 
sequence.  When compared to phage display libraries, OBOC peptide libraries are 
generally smaller however they potentially still contain millions of sequences.   
However, OBOC peptides have the advantage of being able to contain unnatural 
amino acids, D-amino acids as well non-peptide structures.  For drug or imaging agent 
development this is a powerful tool because, as previously mentioned, these 
modifications are usually necessary for a peptide to be stable in biological conditions. 
OBOC libraries have been used to discover compounds with high binding affinities to 
specific receptors; examples include cyclic peptides which bind to breast cancer cell 
lines,
33
 cyclic peptides which bind in high affinity to the somatostatin receptor which is 
over-expressed in certain tumours,
34
 and linear peptides which interact with RGD 
proteins.
35
  These individual beads can then be tested against a specific target to 
determine which beads contain a bioactive peptide sequence.  Like phage display 
libraries, the bioactive peptide sequences must be identified. 
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1.5  Deconvolution and Identification of Peptide Sequences 
 
The two primary methods in order to identify unknown peptide sequences are 
Edman degradation and tandem mass spectrometry.  Reported in 1950, Edman 
degradation involves the use of phenylisothiocyanate which reacts with a free amine 
present at the N-terminus of the peptide to form a cyclical derivative that contains the 
original terminal amino acid.  This can then be removed from the N-terminus of the 
peptide without disrupting any other amino acid monomers to form a 
phenylthiohydantoin amino acid derivative.
36
   
 
Scheme 1.1  Edman degradation utilizing phenylisothiocyanate to form a 
phenylthiohydantoin derivative. 
 
 
Because the side chains are present in this derivative, original amino acid identity 
can be identified by chromatography and mass spectrometry.  This method is useful as it 
requires a minimal amount of peptide, is capable of unambiguously identifying any 
natural amino acid based on their side chain and the ability to sequence peptides directly 
from a solid support.  However, Edman degradation has a number of limitations.  The 
process is time-consuming and prohibitively expensive when identifying a large number 
of peptides.  Further, there is a requirement of an N-terminal amine which is not usually 
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desirable in imaging probe development due to a general lack of biological stability 
associated with peptides containing free N-terminus. 
Tandem mass spectrometry relies on the ionization of the peptide, either through 
ESI (electrospray ionization) or MALDI (matrix-assisted laser desorption/ionization) 
techniques.
37, 38
  A peptide ion is identified and subsequently fragmented and the resulting 
ions can then be used to identify the peptide sequence.  This method is fast, economical 
and has few prerequisites in terms of the peptide’s structure.  For example, tandem mass 
spectrometry can be used to identify peptides with acetylated N-termini as well as non-
peptide like motifs.  Tandem mass spectrometry is also effective in the presence of 
impurities which are common in library screening.
39
  However, in most cases prior to 
sequencing, peptides need to be cleaved from solid support.  Further, the amino acids 
leucine/isoleucine and glutamine/lysine are isobaric and therefore indistinguishable via 
common mass spectrometry methods.
40
  In addition, peptide fragmentation is largely 
sequence specific; individual peptides might not produce all required fragments for 
unambiguous sequence determination.
41  
Mass spectrometry for peptide identification can 
be useful in screening large numbers of peptides for use in nuclear medicine because of 
the versatility allowed in the structure of the bioactive molecule. 
There is a wide array of combinatorial tools available in order to find bioactive 
peptide sequences for use in discovering new targeting entities.  These libraries can 
provide an alternative or complementary method to the rational design process. 
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1.6  Organometallic OBOC Peptide Libraries 
 
Molecular imaging agents are not often developed via the combinatorial approach 
due to a number of difficulties associated with the technique.  Regardless of the method 
employed, testing targeting entities for bioactivity fails to take into account the rest of the 
potential imaging agent.  The targeting entity is only one portion of an imaging agent.  In 
addition to the targeting entity, an imaging entity containing a radionuclide, a chelate or 
prosthetic group and occasionally a linker to attach the imaging entity to the targeting 
entity, is required.  This presents the problem where after testing for bioactive peptide 
sequences and determining their identity, a subsequent modification is always necessary 
to add an imaging moiety.  In the case of small peptides (<2000 Da) and small molecules, 
the addition of a metal chelate and possibly a linker can account for a significant portion 
of the overall mass of the potential imaging agent.
42
 This can dramatically change the 
bioactivity of the targeting entity.
 43, 44
   A demonstration of this is shown by the reduction 
of the binding affinity of the 5-iodobenzovesamicol from an IC50 = 2 nM to an IC50 = 280 
nM upon the addition of a technetium-99m chelate as shown in Figure 1.7.
45
 
 
Figure 1.7  5-iodobenzovesamicol and the compound with a technetium chelate.  The 
addition of the imaging moiety decreases binding affinity by over 100 fold. 
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In general, as targeting entities, either small molecules or peptides, become larger, 
the effect of the imaging entity on the binding affinity becomes less drastic.  However, 
even moderately sized peptides have been shown to be influenced significantly by metal 
chelates.  An example of the addition of rhenium(V) and technetium(V) complexes to a 
somatostatin receptor-binding peptide, containing nine amino acids, with an initial 
binding affinity of 1.8 nM results in the decrease in binding affinity by approximately 
eleven fold.
46
  Also, the addition of a large chelation system can affect the lipophilictiy 
and electronic properties of the compound, as well as altering the conformations of the 
molecule.  All of these can potentially have negative effects on the binding affinity such 
that the peptide sequence is no longer viable as a molecular imaging agent. 
This is an inherently inefficient system because after identifying bioactive peptide 
sequences, the next step is to alter the properties of the compound.  The addition of an 
imaging entity to a targeting entity is especially troublesome during high throughput 
library screening because knowledge of how the targeting entity binds to the target as 
well as its conformation in three dimensions is not usually known; this results in a 
general lack of understanding as to how the addition of an imaging entity might lower the 
initial peptide’s binding affinity.  Because of the problems associated with the addition of 
an imaging moiety, it is apparent that the development of imaging agents poses unique 
challenges of which new methods are required in order to facilitate their discovery. 
Therefore, in order to counter these problems, the development of an 
organometallic OBOC peptide library is proposed.  The introduction of a radionuclide 
surrogate into the peptide library prior to screening has the potential to overcome the 
problems associated with using traditional peptide libraries to discover molecular 
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imaging agents.  This method has the potential to account for changes in binding affinity 
due to radionuclide incorporation; there also exists a possibility to screen for bioactive 
peptide sequences which only show activity when a radionuclide is present.  This type of 
compound would not have been identified using traditional techniques. 
Rhenium is used as a non-radioactive surrogate for the technetium-99m 
radionuclide.  Technetium-99m is the most widely used radionuclide in modern nuclear 
medicine accounting for approximately 85% of radiopharmaceutical injections.  Because 
non-radioactive isotopes of technetium do not exist, rhenium is often used to mimic the 
chemical properties of technetium.  Rhenium is located directly below technetium in the 
periodic table, and due to the lanthanide contraction, has similar size, coordination 
properties and bond lengths.
47
 As such, a rhenium(I) tricarbonyl containing OBOC 
peptide library is proposed for identification of potential technetium-99m molecular 
imaging agents.  A non-radioactive isotope of rhenium is to be attached via a chelation 
system to the N-terminus of solid support-bound peptides in an OBOC library.  The 
decision to utilize one-bead, one-compound libraries is the result of a need to create a 
large library for lead compound discovery in order to validate an organometallic library 
method.  Phage display libraries are biological in nature and limited to natural amino 
acids, as such it is not compatible with the addition of organometallics.  When 
synthesized, the organometallic OBOC peptide library can be tested against targets useful 
in disease diagnosis to develop new potential imaging agents. 
The potential also exists to utilize this method on a wide variety of radionuclide 
imaging moieties.  Because of the different size and coordination spheres of many 
different radionuclides, this method is not limited to the use of rhenium(I) tricarbonyl 
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metal cores, but can be expanded to include any radionuclide in any oxidation state.  This 
method has the potential to be a versatile and universal way to develop molecular 
imaging agents.  Furthermore, it would be possible to create an organometallic OBOC 
peptide library containing multiple different types of chelates or radionuclides, in order to 
investigate and account for differences such as size and charge while further increasing 
the diversity associated with OBOC peptide libraries. 
The creation and utilization of organometallic OBOC peptide libraries would 
increase the efficiency in developing new peptide-based SPECT and PET imaging agents.  
However, there are a number of preliminary experiments and synthesis that are the first 
steps to create a testable organometallic OBOC peptide library. 
1.7  Thesis Scope 
 
Rhenium(I) tricarbonyl organometallic chelates are investigated as part of the 
development of novel organometallic OBOC peptide libraries.  Rhenium is an especially 
attractive metal for this purpose.  Firstly, the radioactive isotopes rhenium-186 and 
rhenium-188 show much promise in therapeutic nuclear medicine as β- emitters of 1.07 
MeV and 2.12 MeV electrons, respectively.
48
  Secondly, rhenium has very similar 
properties to technetium, which is by far the most widely used and available diagnostic 
radionuclide in modern medicine.  Thus, rhenium is commonly used as a non-radioactive 
surrogate to technetium-99m.  Thirdly, the rhenium(I) tricarbonyl core is unique in that it 
requires comparatively small chelators.  The use of large chelators might not be expected 
to produce many positive results in conjunction with relatively small targeting peptides 
due to the large affects it can exert.  Fourthly, rhenium(I) tricarbonyl chelates can easily 
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hold a variety of charges depending on the chelation system, further allowing the 
investigation into imaging entities’ effects on peptide-target affinity. 
With this information, the initial research into organometallic OBOC peptide 
libraries involves the synthesis and characterization of rhenium(I) tricarbonyl chelates 
holding different charges and with the ability to be covalently bound to a peptide 
targeting entity. 
MALDI tandem mass spectrometry will be evaluated as a method to identify and 
sequence peptides containing rhenium(I) tricarbonyl chelates.  Based on the expense, 
presence of a chelate on the peptide N-terminus and the time-consuming nature of Edman 
degradation, developing a method of tandem mass spectrometry to sequence 
organometallic peptides is the most agreeable, efficient and unconstrained way to create a 
method for identifying organometallic peptides. 
Ultimately, with rhenium-containing peptides and a method in order to identify 
unknown organometallic peptides, an OBOC library will be tested against a useful target 
in order to validate the method.  A target for such an exercise is the GLP-1R (glucagon-
like peptide 1 receptor).  Finding a series of imaging agents selectively targeting this 
receptor would potentially allow for monitoring of type 2 diabetes as well as a way to 
diagnose and treat various insulinomas. 
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Chapter 2:  Synthesis of Rhenium(I) Tricarbonyl Chelates as Imaging 
Entity Surrogates 
2.1 Introduction 
 
The first step in the creation of organometallic OBOC (one-bead, one-compound) 
peptide libraries is the development of the metal chelates that can be incorporated into 
peptide sequences.  These metal chelates are to act as imaging agent surrogates.  The 
surrogates will imitate the size, lipophilicity and charge of an imaging entity without 
emitting radiation.  There are a number of requirements for these metal chelates that are 
imposed by their use as potential imaging agents.  All chelates for targeted molecular 
imaging need to be bifunctional; they need to form complexes with metal radionuclides, 
as well as have a functional group that is able to be attached to the targeting entity.  
Further, the chelate needs to be inert in order to withstand the conditions of not only 
library screening but also be stable to in vivo conditions for extended periods of time.  
Despite these restrictions, there are a wide variety of useful imaging-related metal 
chelates which have been investigated. 
Technetium-99m is the most popular medical isotope in nuclear medicine.  It has 
a half-life that is convenient for imaging, as well as the gamma ray emission energy is 
approximately 140 keV which is ideal for SPECT.
49
  Further, the technetium-99m 
radioisotope is readily available from generators, allowing for widespread use away from 
the cyclotron or nuclear reactor facilities used to create radioactive isotopes.  Also, 
SPECT imaging facilities are much more widespread than the corresponding PET 
facilities, despite the superior properties of positron emission tomography.  Because of 
these reasons, it is desirable to develop 
99m
Tc-based imaging agents.  Unfortunately, 
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technetium is an entirely synthetic element and does not possess non-radioactive isotopes.  
Therefore, rhenium is often used as a non-radioactive surrogate for development, 
characterization and testing of imaging agents.  Rhenium and technetium have very 
similar coordination chemistry, bond lengths as well as having very similar size due to 
the lanthanide contraction.  The atomic radius of rhenium is 137 pm and the 
corresponding radius of technetium is 136 pm.
50
 
 
2.1.2 Development of Rhenium/Technetium(I) Tricarbonyl Cores 
 
Rhenium tricarbonyl has increasingly become the subject of imaging-related 
research.  The rhenium tricarbonyl core was first developed in 1994,
51
 in order to further 
investigate the +1 oxidation state of rhenium and technetium.  The rhenium(I) tricarbonyl 
core incorporates a reduction of size as well as an increased in vivo stability in 
comparison to complexes with other oxidation states of rhenium or technetium.  
However, discovery of useful 
99m
Tc(CO)3
+
 imaging agents has been hindered by the 
development of suitable methods of synthesis in a time frame imposed by imaging.  
When 
99m
Tc is eluted from a generator at an imaging facility, it exists as pertechnate, 
[
99m
TcO4]
-
, and needs to be reduced into the +1 oxidation state.  The first methods 
utilized carbon monoxide gas under pressure and in the presence of a reducing agent such 
as NaBH4.
52
  These methods are not suitable for synthesis in the radiopharmacy as they 
are complicated, time-consuming, use pressurized gas and are unfamiliar.  These 
problems were overcome with the development of fully aqueous preparation of 
99m
Tc(CO)3
+
 utilizing potassium boranocarbonate, K2BH3CO2, which is a source of 
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carbonyl ligands as well as acting as a reductant.
53
  This kit formulation allowed for a 
facile way to create radiolabelled compounds by simply mixing the pertechnate with a 
premade formulation in order to create technetium(I) tricarbonyl.  This method does not 
require pressurized carbon monoxide and has increased the interest developing clinically 
relevant technetium(I) and rhenium(I) tricarbonyl molecular imaging agents.  
 
2.1.3 The Properties of Rhenium(I) Tricarbonyl Complexes 
 
The chemical stability of rhenium(I) tricarbonyl has been extensively 
investigated.  Rhenium(I) tricarbonyl is a low spin d
6
 metal that forms octahedral 
complexes and the metal is considered to be a soft Lewis acid.  The metal centre is 
polarisable and prefers softer Lewis bases.  However, the presence of the three carbonyl 
ligands, facially coordinated, significantly adds to the versatility of ligands available to 
the rhenium(I) oxidation state.  Carbonyl ligands donate electron density through σ bonds 
to the metal core, thereby increasing the stability of electron deficient species.  Further, 
the carbonyl ligands also can accept electron density from an electron abundant species 
through the process of π back bonding.  Carbonyls are strong field ligands because they 
increase the magnitude of the Δoct.  This is due to the π* anti-bonding orbitals of the 
carbonyl ligands with t2g symmetry; the energy of the d
6
 electrons is lowered and 
therefore produces a more stable complex (Figure 2.1). 
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Figure 2.1  Partial molecular orbital diagrams for octahedral complexes of rhenium(I).  
The first diagram shows the splitting associated with ligands which do not accept or 
donate π electrons.  The second diagram illustrates the increase in Δoct associated with 
having ligands which accept electron density, as is the case with carbonyl ligands.  This 
occurs because the symmetry of the π* orbitals and three of the d orbitals of the rhenium 
are identical. 
 
This creates molecular orbitals whereby the rhenium(I) tricarbonyl core can 
accept a wide variety of “harder” ligands then would be expected, and allows for a wide 
variety of chelation systems.  The rhenium(I) tricarbonyl core has shown remarkable 
diversity in the ligands it can accept, forming complexes with amines,
54
 aromatic amines 
(pyridine,
55
 imidazole,
56
 pyrazole
57
), phosphines,
58
 thiols,
59
 thioethers,
60
 alcohols
61
 and 
carboxylates,
62
 among others. 
The non-reactivity of rhenium(I) tricarbonyl complexes in general is also due to 
their high kinetic inertness.  The rhenium(I) tricarbonyl chelates are fully saturated 
complexes and the metal core is generally protected from attack by other ligands. 
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Investigations into the properties of mono-, bi- and tridentate ligands for 
rhenium(I) tricarbonyl cores have been extensive.   Stability and in vivo studies have 
shown the tridentate chelators are the most useful for use in molecular imaging.
63
  Most 
tridentate chelates have been shown to be stable to the atmosphere for long periods of 
time.  Further, in vivo biodistribution studies of tridentate rhenium(I) tricarbonyl show 
complete clearance from the body 24 hours post-injection.  This is a result of minimal 
substitution between the rhenium(I) tricarbonyl chelates and biomolecules in the body 
due to high thermodynamic stability and kinetic inertness of the coordination compound.  
Conversely, bidentate rhenium(I) tricarbonyl chelates show increased retention in the 
kidneys and liver post-injection.  Despite very similar lipophilicity and size, the bidentate 
chelates act very differently.  This is most likely due to the exchange of ligands in 
bidentate systems with water and proteins.  As such, the in vivo kinetic stability of 
bidentate complexes is significantly compromised, leading to the exclusive use of 
rhenium(I) tricarbonyl tridentate chelators for imaging purposes. 
 
2.2 Results and Discussion 
 
Four rhenium(I) tricarbonyl bifunctional tridentate chelates have been synthesized 
for use in an organometallic OBOC peptide library.  A selection of chelates, neutral, 
positively and negatively charged, were synthesized in order to obtain a complete 
assessment of the usefulness of rhenium(I) tricarbonyl chelates in OBOC peptide 
libraries, as there exist imaging agents that contain all of these charge states. 
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Two rhenium(I) tricarbonyl starting materials, [Et4N]2[ReBr3(CO)3] and 
[Re(H2O)3(CO)3]OTf, were initially synthesized from rhenium(I) bromopentacarbonyl 
(Scheme 2.1)  These complexes contain bromo- or aqua- ligands which are labile and 
easily exchanged due to the trans-effect of the carbonyl ligands.  The carbonyl ligands are 
able to accept electron density from the attack of a ligand opposite the position of the 
carbonyl, thereby stabilizing transition states.
64
  The tribromo- complex is mildly soluble 
in organic solvents such as methanol, acetonitrile and DMF which allows for 
incorporation of the rhenium(I) tricarbonyl core into hydrophobic chelates.  Conversely, 
the triaqua core is water-soluble and allows for facile incorporation water soluble 
chelators. 
 
Scheme 2.1   The synthesis of rhenium(I) tricarbonyl starting materials.  Compound 2.1 
contains three labile bromide ligands which can be easily substituted as well as two 
tetraethylammonium counterions.  Comparatively, 2.2 contains three labile aqua ligands 
and exists in an aqueous solution with a triflate counterion. 
 
 
 
 
30 
 
 
 
2.2.1 2-Picolylamino-N,N-Diacetic Acid (N,N,O) Rhenium(I) Tricarbonyl Chelate 
 
The chelation system initially investigated was 2-picolylamino-N,N-diacetic acid 
(PADA).  This is because it forms neutral complexes with rhenium(I) tricarbonyl 
compounds as well as provides three different unique electron donating species; an 
amine, a carboxylic acid and a pyridyl nitrogen.  The Re(CO)3-PADA complex has been 
previously shown to be kinetically stable, enduring acid reflux conditions for 24 hours.
52
  
The molecule is bifunctional as it contains functional groups that form a tridentate 
chelation system, as well as a free carboxylate that is used to attach the chelation system 
to a peptide sequence.  Therefore, it is a good system to test the suitability of rhenium 
tricarbonyl cores in organometallic OBOC libraries. 
Initially, the PADA complex was synthesized via the use of ethyl ester protecting 
groups as shown below: 
 
Scheme 2.2 Synthesis of Re(CO)3-PADA.  Reagents: a) Ethylbromoacetate, NEt3, DMF, 
0
o
C.  b)  KOH, EtOH, 0
o
C.  c)  [Et4N]2[ReBr3(CO)3], MeOH 
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First, using the nucleophilic properties of primary amines, in an SN2 reaction, 2.3 
is formed from picolylamine and ethyl bromoacetate.  A single ethyl ester group was 
saponified to form compound 2.4 utilizing potassium hydroxide in ethanol.  The reaction 
involves a selective deprotection of one ethyl ester to form a carboxylate.  The difficulty 
in this reaction is finding the correct conditions to minimize the instances of both ethyl 
esters of 2.3 undergoing saponification.  The purpose of maintaining an ethyl protecting 
group on a single carboxylate is to stop potential coordination of the rhenium tricarbonyl 
core with two carboxylates, which would leave an undesired by-product.  Although 
conditions were obtained where minimal saponification of both ethyl esters was 
observed, a significant portion of starting material was recovered.  Subsequently, the 
coordination of rhenium through the use of [Et4N]2[Re(CO)3Br3] resulted in the isolation 
of 2.5 by silica gel chromatography.  The subsequent saponification of the remaining 
ethyl ester in compound 2.5 was unsuccessful due to decomposition of the coordination 
compound.  It was decided that because of the difficulty of the selective saponification of 
one ethyl ester as well as the problems with deprotecting the ethyl ester from the rhenium 
coordinated species, a new synthetic method would be applied involving less synthetic 
steps. 
In the second synthetic pathway, the number of synthetic steps required is reduced 
significantly.  The synthesis of 2.6 involves the amine nucleophile of iminodiacetic acid, 
and picolyl chloride hydrochloride.  With the addition of potassium hydroxide, 2.6 was 
synthesized in approximately 40 % yield after recrystallization from hot ethanol. 
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Scheme 2.3 Synthesis of PADA (2.6).   Reagents: a)  1.  KOH, MeOH, reflux 24 h. 2.  
HCl(aq) 
 
Rhenium is then coordinated to form the desired bifunctional PADA-rhenium 
chelate.  The synthesis of 2.7 by this method significantly reduces the number of steps 
required to make large quantities of the desired chelation system.  The pyridyl nitrogen is 
expected to coordinate preferentially to the rhenium(I) tricarbonyl core, resulting in the 
desired tridentate chelate.  Although rhenium coordination to both carboxylate groups 
was observed, the desired neutral coordination compound was easily isolated.  In 
methanol, the neutral coordination compound has low solubility and therefore precipitates 
out of solution, whereas the charged coordination compound does not.  The product was 
then purified by recrystallization from hot methanol resulting in a 58% yield. 
 
Scheme 2.4  Synthesis of Re(CO)3-PADA (2.7).  Reagents:  a)  MeOH, 2.1 
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The product was characterized by 
1
H NMR, 
13
C NMR and HRMS.  The 
1
H NMR 
shows a clear downfield shift of the aromatic proton next to the pyridyl nitrogen due to 
the coordination of the Re(I) metal centre.  Also, the most obvious coordination induced 
change in the 
1
H NMR spectrum is the shift downfield and the splitting associated with 
all of the methylene protons.  Compound 2.6 shows two singlets corresponding to the two 
chemically inequivalent methylene proton classes.  However, due to the creation of a 
chiral centre at the nitrogen amine upon the coordination of the metal centre through the 
carboxylate and pyridyl nitrogen, three AB spin systems are observed (Figure 2.2). 
 
Figure 2.2  
1
H NMR spectrum showing the AB spin systems associated with the 
formation of a stereogenic centre upon Re(CO)3
+
 coordination of the PADA ligand, 
compound 2.7.  Each AB spin system represents two methylene protons, each in a 
different chemical environment. 
 
The 
13
C NMR spectrum shows a downfield shift of the coordinated carboxylate 
carbon atom from approximately 171.3 ppm in MeOH-d4 to 178.6 ppm in dmso-d6 while 
the non-coordinated carboxylate is observed at 169.7 ppm, indicating two unique 
carboxylate environments within 2.7.  This can be rationalized as the loss of electron 
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density on the carbonyl group due to the coordination of a positively charged rhenium(I) 
tricarbonyl metal core.  This provides strong evidence of the formation of the desired 
complex.   
From this synthetic method, it is possible to acquire large quantities of 
bifunctional PADA chelator in order to be used in sequence deconvolution studies and 
peptide library construction. 
 
2.2.2 Bispicolylamino Acetic Acid (N,N,N) Rhenium(I) Tricarbonyl Chelate 
 
A chelate holding an overall positive charge was also synthesized in order to 
investigate a wide variety of the charge states of rhenium(I) tricarbonyl complexes.  
Bispicolylamino Acetic Acid (BPA) has two pyridyl donating nitrogen atoms and an 
amine donating group.  Like PADA, a free carboxylate is used as a functional group to 
attach the compound to a peptide sequence.  The synthesis of BPA follows a similar 
methodology to the PADA ligand as shown in Scheme 2.5. 
 
Scheme 2.5  Synthesis of BPA (2.8).  Reagents:  a)  1. NaOH, MeOH, reflux 24 h. 2. 
HCl(aq) 
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Glycine and picolylchloride hydrochloride, via an SN2 mechanism, form 
compound 2.8.  The resulting ligand is obtained via trituration with cold benzene.  The 
product was difficult to crystallize due to high solubility in a variety of solvents from 
water to THF.  Compound 2.8, under all tested conditions, produced impure red oil.  The 
product is subsequently coordinated with rhenium(I) tricarbonyl utilizing 
[Et4N]2[ReBr3(CO)3] in methanol to produce 2.9. 
 
Scheme 2.6  Synthesis of Re(CO)3-BPA (2.9).  Reagents:  a)  2.1, MeOH, reflux. 
 
The coordination of BPA with rhenium(I) tricarbonyl results in downfield shifts 
of the pyridyl methylene protons as well as splitting due to the loss of chemical 
equivalence in the 
1
H NMR spectrum.  Further, the free carboxylate methylene remains a 
singlet due to the formation of an achiral molecule.  The pyridyl methylene protons 
produce one AB spin system because the protons above and below the plane of the 
macrocycle are not equivalent due their inability to freely rotate.  The 
1
H NMR, 
13
C NMR 
spectra and high resolution mass spectrometry provide strong evidence for the desired 
coordination compound. 
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2.2.3 Nitrilotriacetic Acid (N,O,O) Rhenium(I) Tricarbonyl Chelate 
 
The nitrilotriacetic acid (NTA)-rhenium(I) tricarbonyl complex holds an overall 
negative charge.  The chelate allows for the investigation of negatively charged 
rhenium(I) tricarbonyl compounds for use in organometallic OBOC peptide libraries.  
The chelator contains two carboxylates and an amine nitrogen as potential ligands. 
 
Scheme 2.7  Synthesis of Re(CO)3-NTA (2.10).  Reagents a) NaOH(aq), 2.2 
 
The donation of two carboxylate oxygen atoms to the soft rhenium(I) metal centre 
is expected to be thermodynamically disfavourable due to the non-polarisable nature of 
the ligands.  However, in the absence of any other more favourable donating ligands, the 
complex is formed in 37% yield from a reaction of nitrilotriacetic acid, 
[Re(H2O)3(CO)3]OTf and sodium hydroxide in water.  Initially, the synthesis was 
attempted utilizing [Et4N]2[ReBr3(CO)3].  Although 2.10 was observed by 
1
H NMR 
spectroscopy, there was a mixture of sodium and tetraethylammonium counterions 
present.  The 
1
H and 
13
C NMR spectra show unambiguous evidence of coordination.  
High resolution mass spectrometry also shows the expected mass and isotopic signature. 
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2.2.4 2-Picolylamino-N,N-2-Hydroxybenzyl Acetic Acid (N,N,O) Rhenium(I) 
Tricarbonyl Chelate 
 
The development of a tridentate rhenium(I) tricarbonyl chelate utilizing a phenol 
ligand was desirable due to the ligand’s ability to hold a negative charge and therefore 
form a neutral complex in conjunction with an amine and pyridyl nitrogen as donating 
ligands.  Phenol based chelators have not been utilized extensively in rhenium(I) 
tricarbonyl chemistry.  The softer Lewis basicity of the phenol ligand, in comparison to 
carboxylates, would be expected to form thermodynamically stable complexes with the 
metal core, as well as a very lipophilic outer core due to the phenol aromatic systems 
involved, which is often desirable in imaging.  The lipophilicity allows access to 
hydrophobic binding pockets that are common in enzymes and receptors, allowing for the 
rhenium chelate to be a necessary part of the binding affinity of the imaging probe.
23
 
Recently, phenol, amine and aromatic nitrogen bifunctional systems have been 
investigated by Lim et al., utilizing pendant alkene, cyano and amine functionalities as 
available methods to attach the chelate to a biomolecule with mixed results.
65
  While 
complexes were successfully formed utilizing the alkene and cyano functionalities, most 
likely due to their poor coordination properties, the amine has been shown to 
preferentially coordinate over the phenol forming a positively charged complex. 
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Figure 2.3  Phenol based (N,N,O) coordination of rhenium(I) tricarbonyl.  R = H, -
CH2CH=CH2, -(CH2)2CN.  In these complexes, amines are shown to preferentially donate 
electrons to the rhenium(I) tricarbonyl in comparison to the phenol ligand. 
 
However, utilizing a free carboxylate in a bifunctional chelator has not been 
investigated previously.  One would suspect that a phenol as a Lewis base would be a 
more favourable ligand in comparison to a carboxylate due to the difference in 
thermodynamic stability.  Thus, a synthetic method was developed in order to test this 
hypothesis. 
 
Scheme 2.8  Synthesis of PHA (2.13) and Re(CO)3-PHA(2.14).  Reagents:  a) 1. MeOH 
2. NaBH4.  b) tert-butyl, benzyl, ethyl bromoacetate or benzyl bromoacetate, NEt3, 
MeCN to form 2.12a, 2.12b or 2.12c, respectively  c) 2.12a, TFA, DCM.  d) 2.2, H2O, 
NaOH. 
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A reductive amination reaction utilizing salicaldehyde and 2-picolylamine creates 
2.11 through a yellow imine intermediate.  This compound is then reduced with the 
addition of three equivalents of sodium borohydride.  Compound 2.11 was purified by 
column chromatography.  The basic secondary amine in the presence of the acidic phenol 
results in a poor yield as the compound does not move cleanly on silica.  Isolation and 
purification of the imine intermediate followed by reduction did not improve yields.  A 
reaction with tert-butyl bromoacetate, benzyl bromoacetate or ethyl bromoacetate creates 
2.12a, 2.12b, or 2.12c.  The low yields of the reactions can be explained by the presence 
of a nucleophilic oxygen atom of the phenol functionality.  The tert-butyl ester of 
compound 2.12a is then removed utilizing TFA/DCM to form compound 2.13 in 80% 
yield.  Of note is the presence of the phenol peak in the 
1
H NMR at a downfield position 
of 10-11 ppm for all of the previous compounds. A representative spectra is provided of  
compound 2.12a in Figure 2.4. 
 
Figure 2.4  
1
H NMR spectrum of 2.12a showing the region from approximately 6 ppm to 
11 ppm in CDCl3.  The appropriate aromatic peaks are visible along with a peak at 10.3 
ppm corresponding to the phenol proton. 
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The downfield shift of the phenol can be attributed to the unique chemical 
environment of the phenol proton as it may interact with the tertiary amine, producing 
downfield chemical shift for the phenolic hydrogen.  This compound is then coordinated 
with rhenium(I) tricarbonyl in methanol.  The expectation is that this results in product 
2.14 (Scheme 2.8). 
Compound 2.14 has been characterized by 
1
H NMR, 
13
C NMR and HRMS.  
However, this has led to inconclusive results about the nature of the coordination sphere.  
The spectra are unambiguous in that a tridentate complex has been formed due to the 
splitting of the methylene protons similarly observed in other chelates.  However, 
evidence for coordination of the phenol or the carboxylate group to the metal centre is 
inconclusive.  In figure 2.5, a comparison between the 
1
H NMR spectra of compounds 
2.13 and 2.14 shows an obvious downfield shift of all aromatic protons upon 
coordination.  This provides evidence of tridentate coordination utilizing the phenol. 
 
Figure 2.5  A comparison of the 
1
H NMR spectra obtained from A) un-coordinated 
compound 2.13, and B)  coordinated compound 2.14, in deuterated methanol.  All of the 
aromatic peaks shift downfield as a result of the addition of the rhenium(I) tricarbonyl. 
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In addition, the coordinated complex 2.14 has been observed to produce a 
negative result during the qualitative ferric chloride test for phenol; a positive test results 
in a purple solution if a phenol group is present.  These results lead to the conclusion that 
the phenol is a donating ligand in the coordination sphere.  However, there is also a broad 
peak at 10-11 ppm in DMSO-d6 which could correspond to an extremely downfield 
phenol peak or an upfield carboxylic acid peak.  A downfield phenol peak, although 
easily explained in uncoordinated compounds due to the presence of a tertiary amine in 
close proximity, would not be easy to explain due to the absence of electrons on a 
nitrogen which is acting as a coordinating ligand.  This further adds to the ambiguity of 
the 
1
H NMR spectra obtained from this compound.  Yet, the 
13
C NMR spectrum provides 
evidence that shows a carboxylate shift of 178.5 in DMSO-d6 which is consistent with 
coordination of the carboxylate ligand. 
Because of the conflicting evidence, a protecting group strategy was utilized to 
attempt to unambiguously form a phenol-donating complex.  2.12a was coordinated with 
rhenium(I) tricarbonyl in methanol in order to avoid the presence of a free carboxylate.  
Initially, this route seemed to produce the desired result, however upon further 
investigation by HPLC-ESI, the presence of masses associated with coordinated 
compounds containing methyl esters and free carboxylates and no compound containing 
the tert-butyl ester.  The mechanism of this transformation is unknown.  This reaction 
was also repeated using a benzyl protected carboxylic acid, 2.12b, and the ethyl protected 
carboxylic acid, 2.12c, to the same result.  Verification of the formation of a methyl ester 
was obtained by 
1
H NMR spectroscopy.  The reaction was also repeated in DMF, in an 
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attempt to avoid the trans-esterification.  However, the resulting reaction mixture 
contained a major portion of compound 2.14 by HPLC-MS. 
Because of these results, it was decided to first attach compound 2.13 to a peptide 
chain, and coordinate rhenium(I) tricarbonyl after attachment to a peptide.  This process 
will be discussed in the next chapter. 
 
2.3 Conclusions 
 
This chapter has outlined the successful synthesis and characterization of three 
rhenium(I) tricarbonyl chelates to be utilized in the investigation of organometallic 
OBOC peptide libraries.  These chelates represent neutral, positive and negatively 
charged compounds that provide a representation of the entire spectrum of rhenium(I) 
tricarbonyl chelates.  A fourth phenol-based chelate has also been investigated.  However, 
the coordination of the phenol to the metal core has not been conclusively determined.  
This chelator (2.13) can be used, however, to investigate on resin coordination techniques 
for OBOC library creation. 
 
2.4 Experimental 
2.4.1 General Procedures 
 
All chemicals and solvents were purchased from commercially available sources 
and used without further purification.  Chemicals were purchased from Sigma Aldrich, 
Alfa Aesar or Strem.  Solvents were purchased from Fisher Scientific.  Silica gel 
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chromatography was performed using SiliFlash F60 (230-400 mesh) purchased from 
Silicycle.  Flash silica gel chromatography was performed using a Biotage Isolera Prime 
Flash Purification System.   Analytical HPLC was preformed utilizing a Waters Sunfire 
C18 column 4.6 x 150 mm, 5 µm.  The gradient system utilized consists of acetonitrile + 
0.1% TFA and water + 0.1% TFA.  Ultraviolet absorbance measurements were obtained 
utilizing a Waters 2998 Photodiode Array Detector and mass spectra were obtained via 
electrospray ionization utilizing a Micromass Quatro Micro LCT mass spectrometer.  
NMR data were obtained on a Varian Inova 400 MHz spectrometer or a Varian Mercury 
VX 400 MHz spectrometer.  Deuturated solvents were purchased from Sigma Aldrich.  
Chemical shifts were referenced in respect to residual solvent shifts.  High resolution 
mass spectrometry, electron impact and electrospray, was done utilizing a Finnigan MAT 
8200 or a PE-Sciex API 365, respectively. 
 
2.4.2 Small Molecule Synthesis 
 
[Et4N]2[Re(CO)3Br3], 2.1, was prepared according to a previously published 
literature procedure.
66
  [Re(H2O)3(CO)3]OTf , 2.2, was prepared according to a 
previously published literature procedure.
67
 
2-Picolylamino-N,N-diethylacetate (2.3) 
To a solution of picolylamine (0.78 mL, 7.6 mmol) in DMF (9.8 mL) at 0 
o
C, 
triethylamine (2.48 mL, 17.7 mmol) was added and allowed to stir for 10 minutes.  Ethyl 
bromoacetate (0.84 mL, 7.6 mmol) was added dropwise as the solution was allowed to 
44 
 
 
 
stir.  The solution turned yellow, and a second portion of ethyl bromoacetate (0.84 mL, 
7.6 mL) was added dropwise.  The reaction was allowed to stir for two hours at 0 
o
C.  
Subsequently, the reaction was warmed to room temperature and the solvent was 
removed in vacuo.  The remaining solid was dissolved in 20 mL of ethyl acetate and 
filtered.  The ethyl acetate in the filtrate was removed in vacuo.  The residue was purified 
by silica gel chromatography (EtOAc/NEt3, 99:1).  After purification, 0.96 g of product 
was isolated as yellow oil.  (Yield: 45%).  
1
H NMR (CDCl3) δ  8.54 (m, 1H), 7.68 (m, 
1H), 7.61 (m, 1H), 7.71 (m, 1H), 4.17 (q, 4H, J = 7 Hz), 4.07 (s, 2H), 3.62 (s, 4H), 1.27 
(t, 6H, J = 7 Hz).  
13
C NMR (CDCl3) δ  171.3, 159.0, 149.2, 136.8, 123.2, 122.3, 60.7, 
60.0, 55.0, 14.4.  Mass (EI) (m/z) [M]
+
 calc: 280.1423 obs: 280.1429. 
Potassium (2-picolylamino)-N-ethylacetate-N-acetate (2.4) 
To a solution of 0.5M KOH in EtOH (1.6 mL, 0.8 mmol) at 0 
o
C, 2.1 (0.23 g, 0.8 mmol) 
was added.  The reaction was allowed to stir overnight.  The solvent was removed in 
vacuo and the solid residue was triturated in diethyl ether.  The remaining residue was 
dried in vacuo, resulting in 0.14 g of a yellow solid (Yield: 61%).  
1
H NMR (CDCl3) δ  
8.58 (m, 1H), 7.54 (m, 1H), 7.12 (m, 1H), 7.08 (m, 1H), 4.00 (q, 2H, J = 7 Hz), 3.66 (s, 
2H), 3.21 (s, 2H), 3.03 (s, 2H), 1.15 (t, 3H, J = 7 Hz). 
(2-picolylamino-N-acetate) (N,N,O) rhenium tricarbonyl-N-ethylacetate (2.5) 
To a solution of MeOH (10 mL) and [Et4N]2[Re(CO)3Br3] (0.27 g, 0.35 mmol), 2.4 (0.1 
g, 0.39 mmol) was added.  The solution was allowed to stir overnight.  The solvent was 
removed in vacuo to yield as solid residue.  The residue purified by silica gel 
chromatography (EtOAc).  This yields 0.10 g of white solid (Yield: 53%).  
1
H NMR 
45 
 
 
 
(CDCl3) δ  8.84 (m, 1H), 7.96 (m, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 5.28 (d, 1H, J = 15 
Hz), 4.45 (d, 1H, J = 17 Hz), 4.37 (d, 1H, J = 15 Hz), 4.32 (d, 1H, J = 17 Hz) 4.31 (q, 2H, 
J =  7 Hz), 3.91 (d, 1H, J = 17 Hz), 3.69 (d, 1H, J = 17 Hz), 1.37 (t, 3H, J = 7 Hz) 
Potassium 2-picolylamino-N,N-diacetate (PADA) (2.6) 
To MeOH (20 mL) picolylchloride hydrochloride (0.68 g, 4.13 mmol) was added and 
allowed to stir for 5 minutes.  Potassium hydroxide (0.23 g, 4.13 mmol) was added 
slowly.  The solution begins to turn red and was stirred for 30 minutes; a solid forms.  To 
a separate solution of MeOH (37.5 mL) and potassium hydroxide (0.65 g, 11.5 mmol), 
iminodiacetic acid (0.5 g, 3.75 mmol) was added.  After 30 minutes of stirring, the 
picolylchloride hydrochloride solution was filtered and added dropwise to the 
iminodiacetic acid solution.  The reaction mixture was refluxed overnight.  The reaction 
was allowed to cool to room temperature and was filtered.  The methanol of the filtrate 
was removed in vacuo and the residue was dissolved in water (10 mL) and washed with 
DCM (4 x 10mL).  1 M hydrochloric acid was added to the water solution until neutral 
pH was obtained.  The water was then removed in vacuo.  The remaining residue was 
redissolved in anhydrous methanol and filtered.  The methanol was removed in vacuo and 
the residue was recrystallized in EtOH, yielding 0.45 g of product (Yield:  40%).  
1
H 
NMR (MeOH-d4) δ  8.59 (m, 1H), 7.85 (m, 1H), 7.84 (m, 1H), 7.39 (m, 1H), 4.48 (s, 
2H), 3.71 (s, 4H).  
13
C NMR (MeOH-d4) δ  171.3, 153.2, 150.6, 139.3, 135.3, 135.2, 59.5, 
58.0.  Mass (ES-) [M]
-
 (m/z) calc:  223.0719, obs: 223.0729. 
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2-Picolylamino-N,N-diacetate rhenium(I) tricarbonyl (PADA-Re(CO)3) (2.7)   
To a solution of MeOH (36 mL) and 2.6 (0.22 g, 0.75 mmol), [Et4N]2[ReBr3(CO)3] 
(0.556 g, 0.75 mmol) was added slowly at room temperature.  The reaction was stirred 
overnight, a white precipitate formed.  The reaction mixture was filtered and dried, 
resulting in 0.233 g of product.  (Yield:  58%)  
1
H NMR (DMSO-d6) δ  8.75 (m, 1H), 
8.14 (m, 1H), 7.84 (m, 1H), 7.57 (m, 1H), 5.12 (AB, 1H, J = 16 Hz), 4.73 (AB, 1H, J = 
16 Hz), 4.53 (AB, 1H, J = 17 Hz), 4.30 (AB, 1H, J = 17 Hz), 4.04 (AB, 1H, J = 17 Hz), 
3.63 (AB, J = 17 Hz). 
13
C NMR (DMSO-d6): 197.0, 196.9, 196.7, 178.6, 169.7, 159.5, 
151.7, 140.3, 125.7, 123.9, 67.8, 67.4, 61.5.  Mass (ES+) [M+H]
+
 (m/z) calc:  517.0022, 
obs: 517.0035. 
Bispicolylamino acetate (BPA) (2.8) 
To a suspension of 2-picolylchloride hydrochloride (0.6 g, 3.6 mmol) in water (10 mL), 
NaOH (0.26 g, 6.6 mmol) was added.  The 2-picolylchloride hydrochloride dissolved and 
became red.  Glycine (0.125 g, 1.6 mmol) was added.  The reaction was refluxed 
overnight at 65 
o
C.  The reaction mixture was cooled to room temperature and neutralized 
to pH = 7 using 1 M HCl(aq).  The resulting solution was then washed with DCM.  The 
aqueous layer was then removed in vacuo.  The resulting residue was triturated with 
isopropyl alcohol and filtered.  The filtrate was taken and the solvent removed in vacuo.  
The resulting residue was triturated with cold benzene and filtered.  The filtrate was taken 
and the solvent removed in vacuo.  This resulted in 0.08 g of brown powder (Yield: 
20%).  
1
H NMR (DMSO-d6): δ 8.49 (m, 2H), 7.77 (m, 2H), 7.25 (m, 2H), 7.25 (m, 2H), 
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3.93 (s, 4H), 3.35 (s, 2H).  
13
C NMR (CDCl3): δ 174.0, 158.2, 148.6, 137.2, 122.8, 122.6, 
59.9, 58.5.  Mass (EI+) [M+H]
+
 (m/z) calc: 257.1164, obs: 257.1159. 
Bispicolylamino acetate rhenium(I) tricarbonyl (BPA-Re(CO)3) (2.9) 
To a solution of MeOH (20 mL), [Et4N]2[ReBr3(CO)3] (0.10 g, 0.13 mmol) was added 
and stirred until it dissolved.  2.8 (0.04 g, 0.13 mmol) was dissolved in MeOH (2 mL) 
and added dropwise to the reaction mixture.  The reaction was refluxed for 5 hours.  
Subsequently, the reaction was cooled to room temperature and the solvent was removed 
in vacuo.  The resultant residue was recrystallized from methanol.  This yielded  0.01 g 
product (Yield: 15 %).  
1
H NMR (CD3OD): δ 8.84 (m, 2H), 7.92 (m, 2H), 7.54 (m, 2H), 
7.35 (m, 2H), 5.33 (AB, 2H, J = 17 Hz), 4.98 (AB, 2H, J = 17 Hz), 4.72 (s, 2H).  
13
C 
NMR (CD3OD): δ 212.7, 212.6, 171.2, 162.5, 153.2, 141.8, 127.1, 124.7, 69.4, 69.1.  
Mass (ES+) [M]
+
 (m/z) calc: 527.0491, obs: 527.0481. 
Nitrilotriacetate rhenium(I) tricarbonyl (NTA-Re(CO)3) (2.10) 
To a flask containing water (3 mL), nitrilotriacetic acid (0.06 g, 0.3 mmol) was added to 
form a suspension.  0.5 M NaOH(aq) (1.8 mL, 0.9 mmol) was added dropwise, resulting in 
a clear solution.  0.1 M [Re(CO)3(H2O)3]OTf(aq) (3 mL, 0.3 mmol) was added dropwise 
and the reaction was allowed to stir overnight.  The solvent was then removed in vacuo.  
The residue was then dissolved in IPA and filtered.  The filtrate was taken and the solvent 
was removed in vacuo.  The resulting white powder was triturated in DCM and filtered.  
The filtrate was dried, yielding 0.06 g of white powder (37% yield).  
1
H NMR (CD3OD): 
δ 4.21 (s, 2H), 4.03 (AB, 2H, J = 16 Hz), 3.83 (AB, 2H, J = 16 Hz).  13C NMR (DMSO-
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d6): δ 198.4, 198.3, 178.3, 169.9, 68.0, 63.6.  Mass (ES+) [M+H]
+
 (m/z) calc: 505.9474, 
obs: 505.9470. 
2-[(2-Picolylamino)methyl]phenol (2.11) 
To a round bottom flask of MeOH (4.5 mL), salicaldehyde (0.213 mL, 2 mmol) was 
added.  The reaction was stirred and 2-picolylamine was added dropwise (0.206 mL, 2 
mmol).  The reaction immediately became a yellow colour.  After stirring for 2 hours, 
sodium borohydride (0.0756, 2 mmol) was added in four portions over the course of 1 
hour.  The yellow colour disappears and the reaction became clear.  The solvent was 
removed in vacuo.  The residue was dissolved in water and extracted into DCM.  The 
DCM was removed in vacuo and the product was purified by silica gel chromatography 
(EtOAc/MeOH, 9:1).  This yielded 0.22 g of a translucent oil (51% yield).  
1
H NMR 
(CDCl3):  δ 8.60 (m, 1H), 7.68 (m, 1H), 7.21 (m, 3H), 6.98 (m, 1H), 6.87 (m, 1H), 6.79 
(m, 1H), 4.02 (s, 2H), 3.94 (s, 2H).  
13
C NMR (CDCl3): δ 158.2, 157.8, 149.4, 136.7, 
128.8, 128.6, 122.7, 122.4, 122.3, 119.0, 116.4, 53.1, 51.7.  Mass (EI+) [M+H]
+
 (m/z) 
calc:  214.1106, obs: 214.1106. 
2-Picolylamino-N,N-2-hydroxybenzyltert-butyl acetate (2.12a) 
To a stirred round bottom flask containing MeCN (4.5 mL), 2.11 (0.28 g, 1.3 mmol), tert-
butyl bromoacetate (0.19 mL, 1.3 mmol) and triethylamine (0.18 mL, 1.3 mmol) were 
added.  The reaction was allowed to stir overnight after which it became a dark yellow 
colour.  The solvent was subsequently removed in vacuo, and the obtained residue was 
dissolved in EtOAc.  The EtOAc was then filtered to remove an insoluble white powder 
and the solvent from the filtrate was removed in vacuo.  The product was then purified by 
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silica gel chromatography [EtOAc].  The resulting fractions produced 0.13 g of product 
as a yellow oil (35% yield).  
1
H NMR (CDCl3): δ 10.32 (br, s, 1H) 8.58 (m, 1H), 7.68 (m, 
1H), 7.35 (m, 1H), 7.20 (m, 2H), 7.02 (m, 1H), 6.91 (m, 1H), 6.79 (m, 1H), 3.96 (s, 2H), 
3.89 (s, 2H), 3.32 (s, 2H), 1.48 (s, 9H).  
13
C NMR (CDCl3): δ 170.3, 157.7, 157.5, 149.0, 
136.8, 129.7, 129.2, 123.3, 122.4, 122.1, 119.0, 116.5, 81.8, 58.9, 56.6, 55.0, 28.1.  Mass 
(EI+) [M+H]
+
 (m/z) calc:  328.1787, obs: 328.1775. 
2-Picolylamino-N,N-2-hydroxybenzyl, benzyl acetate (2.12b) 
This compound was synthesized in an identical fashion to 2.12a, except for the utilization 
of benzyl bromoacetate in replacement of tert-butyl bromoacetate.  The product was then 
purified by silica gel chromatography [EtOAc].  The resulting fractions produced 0.13 g 
of product as a yellow oil (25% yield).  
1
H NMR (CDCl3): δ 10.33 (br, s, 1H), 8.57 (m, 
1H), 7.67 (m, 1H), 7.38-7.29 (m, 6H), 7.20 (m, 2H), 6.99 (m, 1H), 6.91 (m, 1H), 6.78 (m, 
1H), 5.18 (s, 2H), 4.02 (s, 2H), 3.92 (s, 2H), 3.49 (s, 2H).  Mass (EI+) [M]
+
 (m/z) calc:  
362.1630, obs: 362.1643. 
2-Picolylamino-N,N-2-hydroxybenzylethyl acetate (2.12c) 
This compound was synthesized in an identical fashion to 2.12a, except for the utilization 
of ethyl bromoacetate in replacement of tert-butyl bromoacetate.  The product was then 
purified by sildeica gel chromatography [EtOAc].  The resulting fractions produced 0.13 
g of product as a yellow oil (25% yield).  
1
H NMR (CDCl3): δ 10.29 (br, s, 1H), 8.58 (m, 
1H), 7.69 (m, 1H), 7.34 (m, 1H), 7.21 (m, 2H), 7.04 (m, 1H), 6.91 (m, 1H), 6.79 (m, 1H), 
4.20 (q, 2H, J = 7 Hz), 3.99 (s, 2H), 3.91 (s, 2H), 3.43 (s, 2H), 1.28 (t, 3H, J = 7 Hz). 
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2-Picolylamino-N,N-2-hydroxybenzyl acetate (2.13) 
To a flask containing DCM (5 mL), 2.12a (0.48 g, 1.4 mmol) was added producing a 
yellow solution.  TFA (5 mL) was added dropwise and immediately turned the solution 
clear.  The reaction was stirred for 3 hours and the solvent was removed in vacuo.  The 
resulting residue was purified by flash silica gel column chromatography (EtOAc/MeOH, 
8:2).  The pure fractions produced 0.31 g of product as a white powder (80% yield).  
1
H 
NMR (CD3OD): δ 8.58 (m, 1H), 7.83 (m, 1H), 7.48 (m, 1H), 7.38 (m, 1H), 7.24 (m, 2H), 
6.85 (m, 2H), 4.31 (s, 2H), 4.29 (s, 2H), 3.56 (s, 2H).  
13
C NMR (CD3OD): δ 171.8, 
158.0, 154.2, 150.5, 139.1, 133.0, 132.1, 125.2, 125.1, 121.1, 119.6, 116.9, 59.4, 57.1, 
56.4.  Mass (EI) [M]
+
 (m/z) calc:  272.1161, obs:  272.1149 
2-Picolylamino-N,N-2-hydroxybenzyl acetate rhenium(I) tricarbonyl (PHA-Re(CO)3) 
(2.14) 
To MeOH (20 mL) in a round bottom flask, [Et4N]2[ReBr3(CO)3] (0.101 g, 0.13 mmol) 
was added.  The solution was stirred for 10 minutes until the solution went clear.  2.13 
(0.04 g, 0.13 mmol) was added.  The solution was stirred under reflux for 5 hours.  The 
solution was allowed to cool to room temperature and the solvent was removed in vacuo, 
producing a white powder.  The powder was triturated in water and filtered.  The 
resulting filtrand was dried in vacuo producing 0.02 g of a white powder (20% yield).  
1
H 
NMR (DMSO-d6): δ 10.17 (br s, 1H) 8.78 (m, 1H), 8.10 (m, 1H), 7.13 (m, 1H), 7.57 (m, 
2H), 7.29 (m, 1H), 6.98 (m, 1H), 6.91 (m, 1H) 4.82 (AB, 1H, J = 16 Hz), 4.76 (AB, 1H, J 
= 13 Hz), 4.61 (AB, 1H, J = 13 Hz), 4.39 (AB, 1H, J = 16 Hz), 4.23 (AB, 1H, J = 17 Hz), 
2.99 (AB, 1H, J = 17 Hz) .  
13
C NMR (DMSO-d6): δ 178.5, 159.3, 156.1, 151.8, 140.3, 
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133.4, 130.5, 125.7, 124.0, 119.1, 119.0, 115.9, 67.3, 65.6, 60.23.  Mass (ES+) [M+Na]
+
 
(m/z) calc:  565.0385, obs: 565.0362. 
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Chapter 3:  Investigation into the Fragmentation of Organometallic 
Peptides 
3.1 Introduction 
 
In order to develop organometallic OBOC (one-bead, one-compound) peptide 
libraries, investigation of an amino acid sequencing method is necessary.  Because of the 
nature of OBOC libraries, the identity of the compound present on a specific bead is 
unknown as OBOC libraries are non-spatially addressable.  As such, the synthesis of 
organometallic peptides and the examination of their fragmentation patterns by to 
MALDI tandem mass spectrometry are investigated herein. 
 
3.1.1 Peptide Synthesis 
 
The synthesis of peptides often utilizes a well known methodology involving the 
use of orthogonal protecting groups and the sequential addition of amino acids on solid 
polymer support resin, known as solid phase peptide synthesis.  This technique was 
initially reported by Merrifield in order to overcome difficult and time consuming 
solution phase peptide synthesis.
68
  The most common technique in solid phase synthesis 
utilizes an Fmoc (fluorenylmethyloxycarbonyl) protecting group for the backbone amines 
of the amino acids.  These groups are base labile and removed with piperidine in DMF.  
The side chains of the amino acids are protected with a variety of acid-labile groups, the 
identity of which depends on the nature of the amino acid.  Common side-chain 
protecting groups include Boc (tert-butoxycarbonyl) for amines, tert-butyl ethers for 
alcohols and tert-butyl esters for carboxylic acids, among many others. 
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The synthesis of peptide sequences on a solid polymer support follows an iterative 
procedure of addition and deprotection of amino acids.  First, an Fmoc-protected amino 
acid is added to the resin through a nucleophilic acyl substitution reaction.  The free 
amine on the resin and the carboxylate of the Fmoc-amino acid react to form a peptide 
(amide) bond.  The Fmoc group is necessary in order to avoid multiple additions of 
amino acids to the peptide chain.  However, this reaction is slow due to the relative 
stability of carboxylates in comparison to amides and the moderate nucleophilicity of 
amines.  As such, the addition of coupling agents is necessary in order to increase the rate 
of this reaction (Scheme 3.1). 
 
Scheme 3.1  A diagram of the removal of an Fmoc group and the addition of a second 
amino acid to a resin bound amino acid.  This process is repeated until the desirable 
peptide is synthesized. 
 
After the addition of the Fmoc-amino acid, the removal of the Fmoc group from 
the peptide backbone is accomplished through the use of most commonly 
piperidine/DMF.  These two steps can then be repeated with different Fmoc-amino acids 
such that the desired peptide sequence can be created. 
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After a peptide has been synthesized, the side-chain protecting groups are 
removed via the addition of acid, most commonly TFA (trifluoroacetic acid).  The 
reagent used to cleave the acid-labile side chain protecting groups usually contains a 
small percentage of scavenging agents such as water, phenol or triisopropylsilane.  The 
purpose of the addition of the scavenging agents is to react with electrophiles created 
from the cleavage of protecting groups, such as t-butyl cations.  This is necessary in order 
to avoid the reaction of these electrophiles with the peptide chain. 
There are a wide variety of solid-support resins available to be used.  The general 
formulation of a solid-support involves the presence of an insoluble polystyrene cross-
linked backbone on which PEG (polyethylene glycol) groups are attached.  The PEG 
groups contain a functional group which a peptide can be built upon; the type of 
functional group depends on the type of resin used, and their purpose is primarily to 
provide a method to remove the peptide from the resin after complete synthesis. 
Utilizing standard Fmoc solid phase peptide synthesis procedures, organometallic 
peptides can be synthesized and mass spectrometry can be used to investigate amino acid 
sequencing protocols for organometallic OBOC peptide libraries. 
 
3.1.2 Mass Spectrometric OBOC Sequencing Methods 
 
 A number of mass spectrometric methods have been utilized in order to 
deconvolute compounds present in OBOC libraries in addition to Edman degradation.  
Ladder peptide synthesis, partial Edman degradation-MS (PED-MS), tagging techniques 
55 
 
 
 
and tandem mass spectrometry have all proven to be useful techniques for identification 
of bioactive compounds. 
 Ladder peptide synthesis involves an additional synthetic step during OBOC 
library synthesis.  After each amino acid coupling, a small percentage of the peptide 
chains are “capped” such that subsequent amino acid additions do not react with the 
“capped” molecules.69  After screening an OBOC library, mass spectrometry can identify 
all peptide sequences present on bead, and the difference between the peaks, 
corresponding to terminated peptide sequences has been shown to reveal the identity of 
the sequence.
70
  However, the presence of truncated peptides, acting as contaminants 
during library screening, is not desirable.  
 PED-MS is similar to ladder peptide synthesis as a single OBOC bead will 
contain a series of truncated peptide sequences.  Edman degradation is performed on a 
bead-bound peptide and with the addition of a percentage of capping agent.  A small 
amount of peptide sequences will be terminated by the capping agent after each 
degradation step.  Fmoc, Nic-OSu
71
 and phenyl thiocyanate
72
 groups have been shown to 
be useful for this strategy.  The beads are then analyzed by mass spectrometry, and the 
difference in mass between truncated peptides allows for identification.  The benefit of 
this technique over ladder synthesis is that all truncation is done after library screening.  
Recently, Thakkar et al. utilized PED-MS to sequence peptoid compounds from an 
OBOC library using Fmoc capping groups for sequence termination.
73
  Additionally, 
PED-MS has been used to identify peptide-glycoprotein interactions from OBOC library 
screening.
74
  The main drawback associated with PED-MS is the requirement of peptides 
to contain free N-terminal amines.  
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Figure 3.1  The general procedure of peptide deconvolution through the use of ladder 
synthesis and partial Edman degradation coupled with mass spectrometry. 
  
 Tagging methodologies are also popular techniques in screening OBOC libraries.  
A small percentage of the bead will contain a tag which can reveal the identity of the 
“hit” compound from an OBOC library.  This technique is commonly used in small 
molecule OBOC libraries because of the difficulty in identifying a large number of small 
molecules as first reported by Liu et al.
75
  Additions of amino acids on the bead 
corresponding to an addition of specific group to the small molecule, allow a small 
molecule to be identified by peptide mass spectrometry.  Moreover, this technique has 
been utilized to test and identify cyclic peptides acting on breast cancer cell lines from 
OBOC libraries.
76
  Additionally, the identification of isobaric amino acids is possible 
because the corresponding amino acid tag can be arbitrarily assigned to provide 
maximum possible information.  The problem of interference between the tagging 
sequence and the bioactive compound has largely been overcome by the creation of 
biphasic solid phase support which allows for the synthesis of the tag on the interior of 
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the bead, and the bioactive compound on the exterior (Figure 3.2).
77
  Limitations of such 
a procedure include an increase in synthetic steps and expense as well as the potential for 
decreased detectability of peptide due to the smaller amounts present on the bead. 
 
 
Figure 3.2  The utilization of linear peptides to code for bioactive cyclic peptides on a 
single bead.  The inner core of the bead holds the tagging linear peptide and can be 
sequenced by MS methods in order to identify the cyclic tripeptide. 
 
 Tandem mass spectrometry is also an important technique that involves the 
ionization of peptides utilizing most commonly ESI (electrospray ionization) or MALDI 
(matrix-assisted laser desorption/ionization) methods.  Electrospray ionization commonly 
produces multiply charged ions and can be used in conjunction with liquid 
chromatography,
78
 while in utilizing MALDI the singly charged mass ion is observed.  
The ions formed are then separated based on their m/z ratio and subsequently fragmented.  
The ionic fragments that are produced can reveal information about the connectivity of 
the peptide.  Tandem mass spectrometry is a very convenient method for OBOC peptide 
sequencing because it is able to quickly and economically provide sequences in a 
relatively high-throughput manner.  The use of a UV MALDI laser to cleave peptides 
attached to beads via a photolinker,
79
 as well as the sequencing of peptides through 
MALDI laser cleavage combined with tandem mass spectrometry
80
 have been reported.  
Additionally, a combination of ladder synthesis and on-bead mass spectrometric 
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sequencing has also been reported.
81
  However, sequencing of OBOC libraries containing 
octa- and pentapeptides via both on-bead and solution-phase MALDI tandem mass 
spectrometry has revealed an increase in spectrum quality via solution phase analysis.
82
 
 There are a wide-variety of OBOC sequencing methods available in the 
identification of bioactive compounds on “hit” beads.  However, when developing an 
amino acid sequencing method applicable to organometallic peptides, various other 
considerations need to be examined.  The properties of the imaging entity surrogate; the 
presence of rhenium(I) tricarbonyl chelates need to be taken into account as well as the 
position of the chelate on the N-terminal amine of the peptide chain.  Tandem mass 
spectrometry was chosen as a tool to further investigate the deconvolution of 
organometallic OBOC peptide libraries. 
 
3.1.3 Tandem Mass Spectrometry and Peptide Fragmentation 
 
An investigation to observe the affects of the addition of the organometallic 
species affects the ionization or fragmentation of peptides is necessary in order to 
determine an appropriate method for amino acid sequencing.  Further, if the chelate itself 
forms fragmentation products, these need to be identified.  A variety of MALDI spectra 
of rhenium(I) tricarbonyl metal cores have previously been reported.  In an investigation 
of porphyrin rhenium(I) tricarbonyl compounds by Toganohn et al., MALDI results have 
shown a variety of prominent mass peaks in the spectrum of the precursor depending on 
the compound.  The most common peak reported is the result of the loss of all three 
carbonyl ligands resulting in a [M-3(CO)]
+
 peak.
83
  Conversely, the MALDI results from 
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a vitamin B12 compound modified with a rhenium(I) tricarbonyl chelate, show the 
presence of primarily signals assigned to [M-CO]
+
 and [M-2(CO)]
+
, in addition to [M]
+
 
peak.
84
  In these cases, carbonyls were readily discharged from the molecule, depending 
on the type of coordination environment.  If this is observed for peptide sequencing 
applications, it could complicate organometallic peptide sequencing due to a number of 
low intensity peaks as well as removal of metallic carbonyls in fragmentation.  Therefore, 
the identity of peaks might be ambiguous if it is unknown how many carbonyls the 
fragment contains.  From these reported results, it would seem that the removal of 
carbonyls in MALDI mass spectrometry is highly dependent on the coordination 
environment of the metal core and therefore it is prudent to investigate the fragmentation 
properties of rhenium(I) tricarbonyl tridentate chelates. 
Fragmentation though mass spectrometry for determining amino acid sequences 
in peptides is dependent on the ability of peptides to produce well defined series of 
peptide fragments which correspond to individual amino acids (Figure 3.3). 
 
Figure 3.3  A generic tetrapeptide holding a positive charge on the N-terminus.  This 
compound is fragmented through CID (collision-induced dissociation)  The a2 and b2 
fragments are N-terminal fragments while the x2 and y2 fragments are C-terminal. 
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The types of fragments shown above can be classified into two types of peptide 
fragments.  The a and b fragments maintain a charge on the N-terminus of the peptide.  
Conversely, the x and y fragments maintain a charge on the C-terminus of the peptide.  
The fragmentation pathways are not fully understood, however it is known that b ions in 
have a protonated oxazolone structure
85
 and are an intermediate in the creation of a 
fragments.
86
  The y ions have been shown to be truncated peptide ions as shown in figure 
3.3.
87
  A peptide would be expected to produce a series of fragments corresponding to 
each peptide bond.  The difference in mass between two fragments from the same series 
can be used to identify an amino acid based on the known mass of the side chain.  This 
method is known as de novo peptide sequencing,
88
 and has been shown to be highly 
applicable to small peptide sequences.
89
 
Theoretically, this process is very simple and straight forward.  However, a 
problem associated with peptide fragmentation is that the fragmentation patterns are 
sequence dependent.  The source of the diversity in fragmentation patterns is that amino 
acids have a wide variety of side chains which have dramatically different abilities to 
accept and donate protons.  The mobile proton theory is the most complete explanation of 
peptide fragmentation in tandem mass spectrometry.  The theory states that during the 
initial ionization, basic residues such as amines accept protons from the matrix.  During 
CID, the protons can move to various other parts of the peptide chain such as an amide 
nitrogen or oxygen, which leads to fragmentation.
90
  Therefore, the fragmentation 
patterns depend on where and in which ratios the peptide initially becomes protonated, 
which residues are in close enough physical proximity to receive the proton after 
collisions with gas molecules and which are the most energetically favourable residues to 
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receive the proton.  Thus, the process of peptide fragmentation involves a myriad of 
pathways and potential pathways which need to be understood if the presence or absence 
of a fragment is to be rationalized.  Attempts to simplify de novo sequencing have been 
accomplished by the addition of isotopic signatures on the terminal of the peptide 
sequence in order to more easily identify N- and C-terminal fragments.  A recent example 
of isotopic tagging involves the coupling of bromo pyridyl derivatives to the N-terminal 
of the peptide sequence and allows for identification of the N-terminal fragments via the 
bromine isotopic ratio.
91
  Interestingly, this technique can also be applied in rhenium(I) 
tricarbonyl organometallic OBOC libraries because of the chelates are on the N-terminus 
and rhenium has a distinct isotopic ratio. 
Because peptide fragmentation is not fully predictable, and the identity of the 
amino acids present as well as the three dimensional conformation of the peptide are all 
factors in obtaining mass spectra, the effect of the rhenium(I) tricarbonyl chelates also 
needs to be taken into account.  It is possible that the presence of the organometallic may 
affect proton movement such that there are few favourable fragmentation pathways, and 
it is also possible that the type of chelate present can produce dramatically different 
fragments.  Proteins and peptides are often deconvoluted with the assistance of protein 
databases, whereby fragmentation patterns are compared to thousands of known database 
entries.
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  However, due to the presence of rhenium(I) tricarbonyl chelates in the 
organometallic peptides, these techniques are not available.    Therefore, variables 
associated with organometallic peptide fragmentation need to be addressed in order to 
utilize MALDI tandem mass spectrometry for sequencing organometallic peptides in 
OBOC libraries. 
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3.2 Results and Discussion 
 
This chapter will outline the investigation of the synthesis and fragmentation 
patterns of peptides with N-terminal rhenium(I) tricarbonyl chelates.  Firstly, the peptide 
synthesis and coupling of the organometallic will be discussed.  Secondly, the results of 
MALDI TOF/TOF tandem mass spectrometry with organometallic peptides will be 
shown.  Thirdly, the adaptation of these techniques to OBOC peptide library screening 
conditions is investigated herein. 
 
3.2.1 Organometallic Peptide Synthesis 
 
The synthesis of organometallic peptides proceeds through standard Fmoc solid 
phase peptide synthesis protocols, as discussed previously.  The peptide that was chosen 
to test the influence of a rhenium(I) tricarbonyl chelate on peptide fragmentation, 
compound 3.1, is a compound which has previously been reported to produce fully 
sequencable fragmentation patterns utilizing MALDI TOF/TOF mass spectrometry 
(QATDKFTF-NH2).  The coupling of the organometallic rhenium(I) tricarbonyl was 
shown for PADA, BPA, and NTA compounds (Scheme 3.2). 
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Scheme 3.2  Synthesis of organometallic peptides.  Reagents:  a)  20% piperidine in 
DMF  b)  HBTU, DIPEA, rhenium(I) tricarbonyl chelate in DMF.  Rhenium(I) 
tricarbonyl chelates 2.7, 2.9 and 2.10 were coupled onto the N-terminus of 3.1 to produce 
3.2, 3.3 and 3.4, respectively. 
 
With the peptides synthesized, the Fmoc is removed under standard conditions, 
and the organometallic chelate is coupled to the N-terminus utilizing standard amino acid 
coupling conditions of HBTU, DIPEA and the chelate in DMF.  This is the benefit of 
utilizing bifunctional chelates with a free carboxylic acids; the chemistry of adding a free 
carboxylic acid to an amine is well-known and high yielding.  This results in three 
organometallic peptides, 3.2, 3.3 and 3.4, which contain three different rhenium(I) 
tricarbonyl chelates on the N-terminus, neutral, positive and negative respectively.  These 
compounds were purified by HPLC (high-performance liquid chromatography) and their 
identity confirmed by mass spectrometry. 
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The last organometallic peptide to be synthesized involves the phenol-based 
chelator discussed in the previous chapter.  The PHA chelate (2.14) proved to be of an 
ambiguous coordination sphere; it is unclear if the phenol or the carboxylate is donating 
electrons to the metal core.  Therefore, an attempt to couple 2.14 to the N-terminus of 3.1 
was made under identical conditions as shown in Scheme 3.2.  HPLC analysis showed 
that no reaction had taken place, providing evidence for carboxylate-based coordination 
to the rhenium(I) tricarbonyl core.  Therefore, an alternate method of synthesizing the 
PHA-organometallic peptide was undertaken utilizing on-resin coordination. 
The uncoordinated PHA chelator (2.13) coupled to the peptide compound with a 
free N-terminus.  Potential problems associated with this process are mainly the fact that 
the phenol group remains unprotected during this process.  During the activation of the 
chelate carboxylic acid, there is potential that the phenol group, being a nucleophile, can 
attack the acyl position producing an ester. 
 
Scheme 3.3  A potential reaction during the activation of the carboxylate of 2.13 with the 
coupling reagent HBTU.  The phenol nucleophile might be expected to form a seven 
membered cyclic ring system through intramolecular nucleophylic acyl substitution of the 
activated ester. 
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However, the potential cyclic compound shown (Scheme 3.3), might also be 
susceptible to attack by a nucleophile by the amine of the peptide backbone.  Regardless, 
the PHA chelator was coupled onto the N-terminus of compound.  By HPLC, this 
reaction produced the desired product 3.5, and subsequently [Et4N]2[Re(CO)3Br3] was 
added in a DMF/MeOH mixture with DIPEA to produce the desired organometallic 
peptide shown below.  This product was then purified by preparative HPLC and 3.6 was 
identified by mass spectrometry. 
 
Scheme 3.4  Synthesis of 3.6.  Reagents:  a)  20% piperidine in DMF.  b)  HBTU, 
DIPEA, 2.13 in DMF.  c)  [Et4N]2[Re(CO)3Br3], DIPEA, in MeOH/DMF.  Synthesis of 
Re(CO)3-PHA-QATDKFTF (3.6) proceeds through on an on resin coordination 
methodology. 
 
With four organometallic rhenium(I) tricarbonyl peptides with unique chelates 
synthesized, the peptides were removed from resin, as well as the side chain protecting 
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groups deprotected, utilizing Reagent K, a cleavage solution consisting of 95% TFA: 
2.5% H2O : 2.5% TIS over the course of three hours.  This results in solution phase 
peptides containing a C-terminal amide due to the Rink Amide resin.  The stability of the 
resultant cleaved and deprotected organometallic peptides was investigated by analytical 
HPLC.  3.2 (Re(CO)3-PADA), 3.3 (Re(CO)3-BPA) and 3.6 (Re(CO)3-PHA) peptides 
show no decomposition of the chelate and high conversion rates of chelate coupling.  
However, 3.4 (Re(CO)3-NTA) shows the desired product, the peptide with the chelator 
(loss of rhenium(I) tricarbonyl) and the peptide with a free N terminus (3.1) (Figure 3.4). 
 
Figure 3.4  Crude HPLC UV trace of Re(CO)3-NTA-QATDKFTF-NH2 (3.4) after 
cleavage from resin.  The major peak at 9.90 min represents the desired product with an 
m/z 1399.  The two peaks at 3.91 and 5.58 min show an observed mass of m/z 956 and 
1129 which correspond to the H-QATDKFTF-NH2 and NTA-QATDKFTF-NH2, 
respectively. 
 
It is not surprising that the least stable chelate observed is the Re(CO)3-NTA 
compound (3.4), which contains two donating carboxylates as well as formally holding a 
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negative charge.  The increase in electron density as well as the decrease in steric 
hindrance associated with absence of an aromatic system might produce a metal centre 
with decreased stability towards highly acidic conditions.  Therefore, because of the 
apparent decomposition of 3.4 as shown by HPLC, its use as a chelate in a library is not 
possible due to the absence of a viable purification method when screening a library.  
Nevertheless, all of the desired organometallic peptides were purified by semi-preparative 
HPLC, resulting in pure white solids as products.  Desired products were identified by 
ES+ and MALDI mass spectrometry. 
Through coupling rhenium(I) tricarbonyl chelates to the N-terminal amines of the 
peptide QATDKFTF, the organometallic PADA, BPA and NTA peptides were created.  
A second method of on-resin coordination was utilized to synthesize the organometallic 
PHA peptide.  The fragmentation patterns of these organometallic peptides are then 
investigated utilizing MALDI TOF/TOF mass spectrometry. 
 
3.2.2 MALDI Tandem Mass Spectrometry 
 
In order to investigate the viability of MALDI tandem mass spectrometry as a 
method to deconvolute N-terminal organometallic peptides, initial MALDI studies were 
undertaken on purified organometallic peptides. 
The organometallic peptides were dissolved in water and mixed with a solution of 
CHCA (trans-α-cyano-4-hydroxycinnamic acid).  The solution is then spotted on a 
MALDI plate and is allowed to slowly evaporate resulting in the organometallic peptide 
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and the CHCA co-crystallized.  The matrix absorbs UV light from a laser resulting in 
ablation and the transfer of a proton to the peptide, which can then be detected.  There are 
many known matrices; however CHCA has been reported to be the most useful matrix for 
short peptides.  The mass spectrum obtained shows the expected mass peaks for all of the 
organometallic peptides, with the associated rhenium-185/187 isotopic signature. 
 
Figure 3.5  MALDI MS precursor ion spectrum for 3.2.  The organometallic peptide has 
the expected rhenium 185/187 isotope ratio.  [M+H]
+
 m/z calc: 1432.49 obs: 1432.50 
(rhenium-187 peak). 
 
The desired mass is then selected for further fragmentation.  Both rhenium 185 
and rhenium 187 peaks were selected for fragmentation.  The results of these MS/MS 
spectra indicated that despite the increased intensity of the rhenium-187 peak, when the 
rhenium-185 peak is selected, the N-terminal fragments are easily and unambiguously 
identified due to the isotopic signature present in the MS/MS spectrum.  This isotopic 
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“doublet” is not obvious in the rhenium-187 tandem mass spectrum.  The product ion 
spectrum was obtained for the Re(CO)3-PADA-QATDKFTF-NH2 (3.2) (Figure 3.6). 
 
Figure 3.6  The product ion spectrum of compound 3.2.  The corresponding assignments 
of b and y series can be seen at the top of the figure.  The identity of amino acids is 
determined based on the difference between the m/z in two adjacent peaks of the same 
series. 
 
The rhenium-containing peptide chain gives a well defined fragmentation pattern 
that can be used to deconvolute the amino acid sequence.  There are a number of 
identifiable fragment series present in the spectrum; the b and y series of fragments are 
the most abundant as they form a complete series where all amino acid fragments are 
present.  The b1 fragment is the most intense peak in the spectrum, making it the most 
favourable fragmentation pathway for this particular peptide.  A table of the identifiable b 
and y fragments is shown below: 
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Table 3.1  Fragment assignments from series b and y of the product ion spectrum of 
compound 3.2.  [M+H]
+ 
m/z = 1430.5 (rhenium-185 peak) 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b series 
b0 RE-PADA+NH3 492.3   
b1 RE-PADA-Q 603.1 110.8 Glutamine  
b2 RE-PADA-QA 674.2 71.1 Alanine 
b3 RE-PADA-QAT 775.2 101.0 Threonine 
b4 RE-PADA-QATD 890.3 115.1 Aspartic Acid 
b5 RE-PADA-QATDK 1018.3 128.0 Lysine 
b6 RE-PADA-QATDKF 1165.4 147.1 Phenylalanine 
b7 RE-PADA-QATDKFT 1266.4 101.0 Threonine 
b8 RE-PADA-QATDKFTF 1413.5 147.1 Phenylalanine 
 
 
 
y series 
y1 NOT OBSERVED 
y2 TF 266.1   
y3 FTF 413.2 147.1 Phenylalanine 
y4 KFTF 541.3 128.1 Lysine 
y5 DKFTF 656.4 115.1 Aspartic Acid 
y6 TDKFTF 757.5 101.1 Threonine 
y7 ATDKFTF 828.5 71.0 Alanine 
y8 NOT OBSERVED 
 
The peptide is sequenced by obtaining the difference between two adjacent peaks 
of the same series (Figure 3.7). 
 
Figure 3.7  Two adjacent peaks, b4 and b5, from the product ion spectrum of compound 
3.2.  The rhenium isotopic ratio can clearly be seen in each of the peaks, verifying the 
assignment of their identities as N-terminal fragments.  
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The difference of the two peaks corresponds to a mass of 128.1 Da which 
corresponds to a lysine residue.  Figure 3.8 is also an illustration of the rhenium isotopic 
pattern present in the tandem mass spectrum. 
The co-crystallization and MALDI tandem mass spectrometry procedures were 
repeated with all of the organometallic peptides and produced product ion spectra for all 
of the organometallic peptides (Figure 3.8). 
 
Figure 3.8  The product ion spectra of compounds 3.2 (PADA), 3.3 (BPA), 3.4 (NTA) 
and 3.6 (PHA).  The effects of different rhenium(I) tricarbonyl chelates can be seen in the 
fragmentation patterns and intensities of each spectra. 
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From the resultant fragmentation patterns, the correct amino acid sequences of all 
of the peptides could be obtained.  However, there is a considerable variation in the 
observed fragmentation patterns and intensities associated with different chelates on the 
N-terminus of the exact same peptide sequence. 
It is apparent that the presence of a charged chelate has a large impact on the 
fragmentation patterns of the peptide.  The Re(CO)3-NTA peptide shows a significant 
decrease in observable fragments and intensity for all but the b4 ion which has an m/z of 
859.2.  There are no complete series present in this spectrum, roughly half of the b and 
half of the y series are clearly distinguished (Table 3.2). 
Table 3.2  Fragment assignments from series b and y of the product ion spectrum of 
compound 3.4.  The masses of the b8 and y8 ions can be determined because of the known 
mass of the peptide and the N-terminal chelate.  [M+2H]
+ 
m/z = 1397.5 (rhenium-185 
peak). 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 
b1 NOT OBSERVED 
b2 NOT OBSERVED 
b3 RE-NTA-QAT 744.2   
b4 RE-NTA-QATD 859.2 115.0 Aspartic Acid 
b5 RE-NTA-QATDK 987.3 128.1 Lysine 
b6 RE-NTA-QATDKF 1134.3 147.0 Phenylalanine 
b7 RE-NTA-QATDKFT 1235.3 101.0 Threonine 
b8 NOT OBSERVED 1382.4 147.1 Phenylalanine 
 
 
 
y 
series 
y1 NOT OBSERVED 
y2 NOT OBSERVED 
y3 NOT OBSERVED 
y4 KFTF 541.3   
y5 DKFTF 656.4 115.1 Aspartic Acid 
y6 TDKFTF 757.4 101.0 Threonine 
y7 ATDKFTF 828.5 71.1 Alanine 
y8 NOT OBSERVED 956.5 128.0 Glutamine 
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From these two series it is possible to deconvolute the identity of the sequence.  
Despite the fact that the sequence was successfully obtained, the results cast doubt on the 
versatility of utilizing this chelate with a wide variety of unknown peptide sequences.  
The de novo sequencing of peptides is significantly simplified when the compound is of 
known connectivity, as one would expect.  Furthermore, in the precursor mass spectrum, 
approximately 50% decomposition of the chelate is also observed.  This is potentially the 
result of two mechanisms.  Firstly, the compound might be unstable to the co-
crystallization matrix, as CHCA is an acid and 3.4 shows limited stability to TFA.  
Secondly, this might be a result of the ionization process itself.  Decomposition occurs 
with the transfer of protons to the organometallic peptide.  Unfortunately, the combined 
lack of stability to TFA, the decomposition during MALDI and poor fragmentation 
suggest that these chelates are unsuitable for OBOC library screening.  The negative 
chelate may be the cause of the poor fragmentation in a positive mass spectrometry 
experiment.  A potential solution to this problem would be to utilize a negative mass 
spectrometry analysis.  However, this was not pursued due to the fact that the matrix 
remains the same in the negative experiment and will lead to decomposition, in addition 
to the lack of TFA stability. 
Conversely, 3.3 holds a positive charge and if the negative charge has a major 
contribution to the poor fragmentation the of Re(CO)3-NTA peptide, it is expected that 
the positive charge would produce many high intensity fragments due to increased 
conversion of peptide to gas phase ion.  A similar result was obtained recently by Cydzik 
et al. using positively charged tetraethylammonium N-terminal peptides to produce more 
intense fragments.
93
  Indeed this is what is observed with the Re(CO)3-BPA peptide.  The 
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entire b and a series which both correspond to N-terminal charge species are present.  
This is not surprising because the N-terminus of the peptide contains a positive charge.  
There are also no observable y series fragments that correspond to a C-terminal charged 
fragment.  This can be rationalized by the fact that y series fragments generally require 
the movement of the additional proton added by the matrix to the C-terminus.  However, 
since Re(CO)3-BPA-QATDKFTF-NH2 is already positively charged it does not gain a 
proton from the matrix, as verified by the mass of the precursor peaks.  The presence of 
every a series ion is somewhat unique in tandem mass spectrometry utilizing collision-
induced dissociation and rarely reported (Table 3.3).   
Table 3.3  Fragment assignments from series b and a of the product ion spectrum of 
compound 3.3.  The masses of the b8 and a8 ions can be determined because of the known 
mass of the peptide.  The relationship between the a and b series is the loss of a carbonyl, 
m/z = 28.  [M]
+ 
m/z = 1463.6 (rhenium-185 peak). 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b series 
b0 RE-BPA+NH2 527.1   
b1 RE-BPA-Q 638.2 111.1 Glutamine  
b2 RE-BPA-QA 709.2 71.0 Alanine 
b3 RE-BPA-QAT 810.3 101.1 Threonine 
b4 RE-BPA-QATD 925.3 115.0 Aspartic Acid 
b5 RE-BPA-QATDK 1053.4 128.1 Lysine 
b6 RE-BPA-QATDKF 1200.4 147.0 Phenylalanine 
b7 RE-BPA-QATDKFT 1301.5 101.1 Threonine 
b8 NOT OBSERVED 1448.7 147.2 Phenylalanine 
 
 
 
 
 
a series 
a0 NOT OBSERVED 
a1 RE-BPA-Q-CO 610.2   
a2 RE-BPA-QA-CO 681.2 71.0 Alanine 
a3 RE-BPA-QAT-CO 782.2 101.0 Threonine 
a4 RE-BPA-QATD-CO 897.3 115.1 Aspartic Acid 
a5 RE-BPA-QATDK-CO 1025.4 128.1 Lysine 
a6 RE-BPA-QATDKF-CO 1172.4 147.0 Phenylalanine 
a7 RE-BPA-QATDKFT-CO 1273.4 101.0 Threonine 
a8 NOT OBSERVED 1420.5 147.1 Phenylalanine 
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Because of the high intensity, complete fragment series and relative stability of 
BPA peptide (3.3) to acidic conditions, BPA is a candidate for use in OBOC peptide 
libraries.  A potential problem in sequencing unknown peptides would be the large 
number of N-terminally charged fragments might make de novo sequencing difficult due 
to an increasing probability of inappropriate determinations of structure. 
Like the Re(CO)3-PADA peptide, Re(CO)3-PHA-QATDKFTF-NH2 (3.6), also 
forms neutral complexes with rhenium(I) tricarbonyl.  As such, one would expect similar 
fragmentation patterns and peak intensities.  Although the PADA and PHA chelates 
produce the most similar mass spectra of any of the chelates, there are a number of 
differences.  While the b1 peaks for both 3.2 and 3.6, m/z 603.1 and 651.2, respectively, 
are both the base peaks for each spectrum, the relative intensities of peaks present in the 
PHA spectrum are generally lower in comparison to the dominant b1 fragment,.  There is 
a full complement of b series fragments that were used to successfully sequence the 
peptide.  However, there was only one identifiable y peak, y7 with an m/z = 828.5. 
Table 3.4  Fragment assignments from series b of the product ion spectrum of compound 
3.6.  The masses of the b8 ion can be determined because of the known mass of the 
peptide.  [M+H]
+ 
m/z = 1478.5 (rhenium-185 peak). 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b series 
b0 RE-PHA-NH3 540.1   
b1 RE-PHA-Q 651.2 111.1 Glutamine 
b2 RE-PHA-QA 722.2 71 Alanine 
b3 RE-PHA-QAT 823.3 101.1 Threonine 
b4 RE-PHA-QATD 938.3 115 Aspartic Acid 
b5 RE-PHA-QATDK 1066.4 128.1 Lysine 
b6 RE-PHA-QATDKF 1213.4 147 Phenylalanine 
b7 RE-PHA-QATDKFT 1314.5 101.1 Threonine 
b8 NOT OBSERVED 1461.5 147 Phenylalanine 
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Perhaps the most interesting aspect of the behaviour of PHA in the daughter ion 
spectrum is the presence of chelate fragmentation patterns.  These fragments generally 
consist of a loss of an m/z of 106 when compared to b fragments.  These peaks also 
contain the characteristic rhenium isotopic signature indicating the presence of rhenium 
in the fragment.  This shows that these fragments must be N-terminal in nature.  Further, 
these peaks, although not present in a full series, are found over a very large mass range.  
For example, a peak observed at m/z 1374.5 is 106.0 less than the [M+H]
+
 of m/z 1480.5.  
Furthermore, there is a loss of 106.0 from the b1 ion of m/z 651.2.  Because of the 
presence of the mass loss throughout the entire series of b ions, as well as some of the a 
ions, the loss of 106.0 can only be explained by a fragmentation of the chelate (Scheme 
3.5). 
 
Scheme 3.5  The proposed fragmentation mechanism of the phenol-based chelate in 
compound 3.6.  The creation of an orthoquinone methide accounts for the loss of m/z = 
106 observed in the mass spectrum. 
 
This mechanism describes the creation of an orthoquinone methide.  This explains 
the loss of the appropriate mass as well as the maintenance of the uncharged nature of the 
N-terminal chelate required for agreement with the observed fragmentation.  The 
resultant bidentate chelate contains an amide functionality which balances the overall 
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positive oxidation state of the rhenium(I) tricarbonyl.  There are four relatively intense 
fragments that correspond to the loss of a quinone methide (Table 3.5). 
Table 3.5  The observed fragments in the product ion spectrum of compound 3.6 due to 
the loss of an m/z = 106 corresponding to the loss of an orthoquinone methide. 
Series and 
Label 
Fragment Observed m/z 
[M+H]
+
 - 106 Re(CO)3-PHA-QATDKFTF-NH3
+
 - 106 1374.5 
b8 - 106 Re(CO)3-PHA-QATDKFTF - 106 1357.5 
b1 - 106 Re(CO)3-PHA-Q – 106 547.1 
a1 - 106 Re(CO)3-PHA-Q – 106 519.1 
 
From the fragmentation results of the PHA chelate organometallic peptide, it is 
clear that rhenium(I) tricarbonyl chelates are not universally stable to the fragmentation 
conditions.  The additional information obtained from these experiments is important if a 
MALDI TOF/TOF sequencing method is to be used in the screening of organometallic 
OBOC libraries. 
 
3.3 Conclusions 
 
The results of these experiments into the fragmentation patterns of rhenium(I) 
tricarbonyl peptides has provided useful information into the effects of N-terminal 
organometallics on peptide fragmentation.  These results have provided the first de novo 
sequencing of rhenium(I) tricarbonyl containing peptides which provides a foundation for 
further research into the identification of organometallic peptides for use in molecular 
imaging. 
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The same peptide sequence was used with the addition of four rhenium(I) 
tricarbonyl bifunctional chelates that have been directly attached to the peptide N-
terminus.  All of the resulting compounds were successfully sequenced by tandem mass 
spectrometric methods.  The fragmentation patterns of neutral, positive and negative 
organometallics provide an insight into the different effects of the N-terminal chelates.  
The fragmentation patterns are unique between each charge state, most likely the result of 
different three dimensional conformations and mobile proton pathways during collision-
induced dissociation.  Furthermore, PADA and PHA, both neutral chelates, also produce 
different fragmentation patterns.  The steric differences between a carboxylate and phenol 
ring produce unique fragmentation patterns and especially relative intensities between 
peaks. 
Overall, the rhenium(I) tricarbonyl chelates have proven to be extremely stable to 
decarbonylation in MALDI mass spectrometry, in opposition to the literature reports.  
The chelates, in general, have also been shown to be stable to fragmentation conditions, 
with the notable exception of 3.6, producing spectra that can be interpreted to fully 
sequence peptides.  The results of these experiments have shown that MALDI TOF/TOF 
is an appropriate method for deconvolution of organometallic OBOC libraries.  
 
3.4 Experimental 
3.4.1 General procedures and materials 
 
All chemicals and solvents were purchased from commercially available sources 
and used without further purification.  Coupling agents, resin and Fmoc amino acids were 
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purchased from Peptides International (Louisville, KY) or Aapptec (Louisville, KY).  
Solvents and other chemicals were purchased from Fisher Scientific and Sigma Aldrich.  
Analytical HPLC was preformed utilizing a Waters Sunfire C18 column 4.6 x 150 mm, 5 
µm.  Semi-preparative HPLC was preformed utilizing a Waters Sunfire Prep C18 OBD 
column 19 x 150 mm, 5 µm or a Waters Atlantis T3 Prep C18 OBD column, 19 x 150 
mm, 5 µm.  The gradient system utilized consists of acetonitrile + 0.1% TFA (Solvent A) 
and water + 0.1% TFA (Solvent B).  Ultraviolet absorbance measurements were obtained 
utilizing a Waters 2998 Photodiode Array Detector and Mass spectra were obtained via 
electrospray ionization utilizing a Micromass Quatro Micro LCT mass spectrometer.  
MALDI mass spectrometry experiments were done utilizing an Applied Biosystems 4700 
PDS.  This instrument is equipped with an Nd: YAG laser tuned to a wavelength of 355 
nm, with a 200 Hz laser rate operating in reflectron mode and tandem time-of-flight ion 
detectors in series.  The mass spectrometer was calibrated with a mixture of angiotensin I 
(m/z 1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da. 
 
3.4.2 General Peptide Synthesis 
 
Standard Fmoc solid phase peptide synthesis was performed in order to obtain the 
desired peptide with side chain protecting groups.  Rink amide MHBA NH2 resin ( 0.1 
mmol, 0.28 meq/g) containing an Fmoc protecting group was utilized.  The resin was 
swelled with DMF and DCM washes.  The Fmoc was removed with a solution 20% 
piperidine in DMF (2x, 5 min and 20 min, respectively).  The residual deprotection 
solution was removed from resin using DMF and DCM washes.  Fmoc-protected amino 
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acids (0.3 mmol, 3 eq) were dissolved in DMF (0.5 mL) along with HBTU or HCTU (0.3 
mmol, 3 eq) and DIPEA (0.6 mmol, 6 eq).  The amino acids used were Fmoc-Phe-OH, 
Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ala-OH and 
Fmoc-Gln(Trt)-OH.  The solution was then combined with the resin and agitated for one 
hour.  The resin was then washed with DMF and DCM.  This process was repeated as 
second time for one and a half hours.  This deprotection/coupling process was repeated 
for each amino acid.  Chelates were added using similar procedures. 
 
3.4.3 Organometallic Coupling Procedure 
 
Compounds 3.2, 3.3, 3.4 
The chelate (0.4 mmol, 4 eq.) was dissolved in DMF (2 mL/1 mL for PADA (2.7)/BPA 
(2.9) and NTA (2.10), respectively) with HBTU or HCTU (0.4 mmol, 4 eq.) and DIPEA 
(0.8 mmol, 8 eq.) and mixed with peptide containing Rink Amide resin (0.1 mmol).  The 
resin and solution were agitated overnight and subsequently washed with DMF and DCM 
resulting in the desired organometallic peptide. 
Compound 3.6 
The Rink Amide resin (0.1 mmol) and 2.13, the PHA chelator (0.4 mmol, 4 eq.) in 2 mL 
of DMF with HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8 eq.) and mixed 
overnight.  The resin was washed with DMF and DCM resulting in compound 3.5.  Then, 
[Et4N]2[Re(CO)3Br3] (0.2 mmol, 2 eq.) in 1 ml of a 50:50 mixture of MeOH/DMF (v/v) 
with DIPEA (0.2 mmol, 2 eq.) is added to the resin containing compound 3.5.  The resin 
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and solution was mixed overnight.  The resin was then washed with DMF and DCM 
resulting in compound 3.6. 
 
3.4.4 Peptide Deprotection, Cleavage and Purification 
 
The organometallic peptides on resin were mixed with a solution of 95% TFA, 
2.5% H2O and 2.5% TIS (1 mL) for three hours to remove the peptide from resin as well 
as remove side-chain protecting groups.  The resulting solution was cooled on ice and 
cold tert-butyl methyl ether (TBME) (1 mL) was added dropwise to the solution until a 
white precipitate formed.  The solution was then centrifuged at 0
o
C at 3000 rpm for 10 
minutes.  The liquid was decanted and the resulting pellet was mixed with cold TBME (1 
mL) and subsequently centrifuged again under identical conditions to obtain the crude 
peptide. 
The crude peptides were dissolved in water and purified by HPLC and identified 
by mass spectrometry, resulting in white powders. 
Re(CO)3-PADA-QATDKFTF-NH2 (3.2) 
The compound was synthesized via standard solid phase peptide synthesis techniques and 
purified by preparative HPLC (15 min linear gradient 30% solvent A in solvent B to 
70%).  The purity and identity of the compound was assessed by analytical HPLC and 
mass spectrometry, respectively. Purity: 98%. MS (MALDI) [M+H]
+
 m/z calc: 1432.5  
obs: 1432.5. (Rhenium-187) 
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Re(CO)3-BPA-QATDKFTF-NH2 (3.3) 
The compound was synthesized via standard solid phase peptide synthesis techniques and 
purified by preparative HPLC (15 min linear gradient 20% solvent A in solvent B to 
90%).  The purity and identity of the compound was assessed by analytical HPLC and 
mass spectrometry, respectively.  Purity: 93%. MS (MALDI) [M]
+
 m/z calc: 1465.5 obs: 
1465.6. (Rhenium-187) 
Re(CO)3-NTA-QATDKFTF-NH2 (3.4) 
The compound was synthesized via standard solid phase peptide synthesis techniques and 
purified by preparative HPLC with a gradient (15 min linear gradient 20% solvent A in 
solvent B to 90%). The purity and identity of the compound was assessed by analytical 
HPLC and mass spectrometry, respectively.  Purity: 90%. MS (MALDI) [M+2H]
+
 m/z 
calc: 1399.5 obs: 1399.5. (Rhenium-187) 
Re(CO)3-PHA-QATDKFTF-NH2 (3.6) 
The compound was synthesized via standard solid phase peptide synthesis techniques and 
purified by preparative HPLC with a gradient (15 min linear gradient 25% solvent A in 
solvent B to 80%).  The purity and identity of the compound was assessed by analytical 
HPLC and mass spectrometry, respectively.  Purity: 95%. MS (MALDI) [M+H]
+
 m/z 
calc: 1480.5 obs: 1480.5. (Rhenium-187) 
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3.4.5 MALDI Tandem Mass Spectrometry 
 
Purified organometallic peptides were dissolved in water at a concentration of 
approximately 0.02 g/mL.  A portion of the organometallic peptide solution (2 µL) and a 
CHCA solution (2 µL) were mixed for a few minutes.  CHCA solution is a mixture of 
50:50 water/acetonitrile with the addition of 0.1% TFA (v/v) at a concentration of 5 
mg/mL.  A portion of the mixture (0.7 µL) was then spotted onto a MALDI plate in 
duplicate for analysis.  The solvent in the mixture was allowed for evaporate resulting in 
the co-crystallization of the matrix and peptide.  The samples were then analysed via 
MALDI tandem mass spectrometry.  The precursor ion spectra show rhenium-185/187 
isotopic distributions.  The rhenium-185 peak was chosen for fragmentation via collision 
induced dissociation with argon gas.  Tandem mass spectra were obtained and peaks 
assigned via manual de novo peptide analysis. 
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Chapter 4:  The Synthesis and Screening of Organometallic OBOC 
Peptide Libraries 
4.1 Introduction 
4.1.1 OBOC Libraries 
 
OBOC libraries can be used to screen for bioactive molecules against particular 
receptors, enzymes or other targets.  In the previous chapter, MALDI tandem mass 
spectrometry has been shown to provide a useful and efficient method to determine the 
amino acid sequences of organometallic peptides.  Mass spectrometry can then be applied 
to the sequencing of organometallic OBOC peptide libraries.  These libraries have the 
potential to be a powerful tool in developing targeted peptide-based imaging agents. 
Traditionally, OBOC libraries have not been popular in developing imaging 
agents for a number of reasons.  OBOC libraries contain a large number of beads, each 
single bead contains many copies of the exact same compound.  Peptides are thought to 
sometimes be present in unusual conformations in OBOC libraries due to the high 
concentration of peptide on a single bead.
94
  Also, the presence of the polystyrene 
backbone of the bead can also have a large effect on the conformations of peptides.  
Therefore, bioactive peptide hits need to be re-evaluated in solution after the library has 
been screened.  Furthermore, due to the unnaturally high concentration of peptide on 
library beads, false positive hits also can be a problem because of interactions between 
peptides and the many macromolecules present on cell surfaces.  In addition, the initial 
formulation of an OBOC screening method was heavily reliant on manual separation of 
beads for analysis.
95
  This process was inherently slow and low-throughput, further 
discouraging its use.  However, with the application of fluorescence sorting and the 
85 
 
 
 
development of high-throughput mass spectrometry these problems can largely be 
overcome in order to screen libraries efficiently and economically. 
The main advantage to utilizing OBOC libraries is the ability to create a large 
diverse library in which many compounds can be tested against targets.  Moreover, 
OBOC libraries are built through chemical synthesis, and as such, can include a large 
variety of chemical scaffolds.  Aside from naturally occurring amino acids, there are a 
wide variety of unnatural amino acids, D-amino acids, linkers and non-peptide 
components available.  Natural peptides, in general, have short biological half-lives, and 
the addition or replacement of natural amino acids with non-natural mimics increases 
their stability.  Because OBOC peptide libraries can include these non-natural mimics, it 
is a very appealing method for developing peptide-based imaging agents.  Recently, there 
has been an interest in furthering the use of OBOC libraries in developing non-peptide or 
unnatural libraries. 
Aditya et al. recently reported the synthesis and sequencing, through MALDI 
MS/MS, of an OBOC library containing peptide-like compounds with unnatural 
heterocycle side-chains (N-substituted oligo-glycines)
96
 (Figure 4.1).  These types of 
compounds are promising for therapeutic and diagnostic applications because they have 
similar properties to peptides; however they are resistant to biological degradation.  The 
chemistry associated with synthesizing these compounds on the solid-phase is not fully 
developed and results in incomplete and impure libraries 
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Figure 4.1  An example of the peptide-like compounds created in OBOC libraries by 
Aditya et al.  These compounds are similar to peptides in structure, however they are 
expected to have long biological half-lives.  These compounds were sequencing by 
MALDI TOF/TOF. 
 
Another recent example of utilizing unnatural compounds has been shown by 
Goksel et al. in developing drugs against the androgen receptor.  An OBOC peptide 
library containing unnatural amino acids was synthesized and tested for binding affinity.  
This resulted in a number of “hit” sequences deconvoluted through MALDI TOF ladder 
peptide synthesis.  The best hit resulted in the peptide sequence 
SSRXESXXAGEKESRG, where X are β-(2-naphthyl)alanine, β-cyclohexylalanine and 
tryptophan, and the binding affinity measured is 0.47 µM.
97
 
Recently, Bachor et al. have developed OBOC peptide libraries containing N-
terminal quaternary ammonium salts.  Peptides were reacted with iodoalkanes to form 
positively charged N-terminal residues.  The purpose of these positively charged 
ammonium N-terminal residues is to provide increased sensitivity to mass spectrometric 
analysis of peptides,
98
 and has resulted in the successful sequencing of these modified 
peptides.  This methodology bears similarities to the development of organometallic 
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OBOC peptide libraries with rhenium(I) tricarbonyl chelates on the N-terminus of the 
peptide sequence. 
Despite the increased use of OBOC libraries to develop peptide or peptide-like 
compounds, developing imaging agents via this method has been generally neglected due 
to the necessary modifications after screening.  The proposed solution to this problem is 
to develop organometallic OBOC peptide libraries that take into account the effects of the 
imaging entity on the binding affinity of a peptide sequence. 
 
4.1.2 Glucagon-Like Peptide 1 Receptor 
 
The GLP-1R (glucagon-like peptide 1 receptor) is a promising target for 
developing imaging agents.  The receptor is a member of GPCR (G Protein-Coupled 
Receptor) superfamily.  This class of receptors is currently one of the most important 
drug targets in modern medicine as roughly half of all pharmaceuticals target this 
superfamily of receptors.  The endogenous ligand of GLP-1R, glucagon-like peptide 1 
(GLP-1), is a peptide hormone produced in the body which has roles in regulating blood 
glucose in response to nutrient digestion.
99
  GLP-1, in its bioactive form, is a peptide 
containing 29 amino acids which is produced in intestinal L-cells.  GLP-1 receptors are 
found largely in pancreatic beta cells which are responsible for insulin secretion.  
Because of this, the GLP-1R is an important target for treatment of type II diabetes.  
Furthermore, GLP-1R is also an important potential target for imaging of various 
insulinomas.  These cancers often over-express the GLP-1R and a targeting imaging 
agent would be a very useful for diagnosis and monitoring. 
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Glucagon-like peptide 1 is produced through modification of the peptide 
prohormone proglucagon.
100
  The products of the processing reactions result in a number 
of bioactive compounds, such as GLP-2 and glucagon, in addition to GLP-1 which 
usually exists as GLP-1(7-36) with a C-terminal amide.  The binding interactions 
between GLP-1 and its corresponding receptor have been determined through alanine 
scans
101
 and side-chain modifications
102
 to identify the necessary amino acids for binding 
and the potential for imaging entity addition along the backbone, respectively. In 
addition, there have been reports of crystal structure determinations of the GLP-1R N-
terminal extracellular domain with peptide antagonists at a resolution of 2.2 Å
103
 and 
more recently 2.1 Å
104
 to investigate peptide-receptor interactions.  From these results, it 
can be shown the GLP-1R has two distinct binding motifs that GLP-1(7-36) amide 
interacts with simultaneously, with a binding affinity of approximately 0.16 nM.
105
  This 
results in a large number of amino acids of GLP-1 being necessary for binding affinity to 
be maintained.  The alanine scans, side chain modification studies and crystal structures 
have shown that not only are a large number of GLP-1(7-36) amino acids necessary for 
maintenance of binding affinity, these amino acids are also located along the entire length 
of the backbone; therefore, modifications are non-trivial exercises. 
GLP-1, like most naturally occurring peptides, has been shown to have a short 
biological half-life of approximately two minutes.  The poor biological stability of GLP-
1(7-36) is due to the presence of L-alanine in position 8, which is susceptible to cleavage 
by the enzyme dipeptidyl peptidase-IV.
106
  The replacement of the L-alanine with D-
alanine or aminobutyric acid increases the stability of the peptide significantly, allowing 
GLP-1(7-36)amide to be a promising therapeutic and diagnostic pharmaceutical.  A 
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number of GLP-1 analogues have or are currently undergoing clinical trials for treatment 
of diabetes, such as Victoza, which possesses a 97% sequence identity to GLP-1 with the 
addition of a fatty acid to the side chain of one amino acid.
107
  In addition to GLP-1, 
exendin has also been shown to be a high affinity ligand of the GLP-1R.  The exendin 
peptide hormone was isolated from the saliva of the lizard Heloderma suspectum in 
1992.
108
  The peptide possesses a 53% sequence identity to GLP-1,
109
 has a significantly 
longer biological half-life and shows higher binding affinity to the GLP-1R.  Currently, 
the peptide is used for treatment of diabetes through injections under the brand name 
Exenatide. 
Despite the moderate success of GLP-1 and exendin analogues as therapeutic 
pharmaceuticals for treatment of diabetes, imaging agents have yet to be fully developed 
based on these peptide sequences.  Initially, iodine-123 conjugates of GLP-1 and 
exendin-3 were developed as SPECT agents for detection of insulinomas.  The results of 
these studies indicated that the accumulation of the molecular probe in the tumor was 
poor, suggesting that the iodine conjugates were not stable to biological conditions.  
Modification of the exendin-3 peptide at the lysine in the forty position with gallium-68 
and indium-111 chelates led to the creation of [Lys
40
(
68
Ga-DOTA)]-exendin-3 and 
[Lys
40
(
111
In-DTPA)]-exendin-3.  These imaging agents have shown selective uptake in 
subcutaneously insulinoma tumors implanted in mice.
110
  However, there is also 
significant uptake in the kidneys most likely due to the positive charges present on lysine 
and arginine side chains.  Furthermore, recent in vitro studies of a GLP-1 derivative with 
an AEEA (2-aminoethoxy-2-ethoxy acetic acid) linker, [Lys
37
AEEA(
111
In-DOTA)]GLP-
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1 show high binding affinity to the GLP-1R.
111
  However, similar problems with in vivo 
distribution of the imaging agent are observed. 
Despite the development of promising imaging agents with high binding affinity 
to the GLP-1R developed based on the scaffolds of GLP-1 and exendin, there are 
problems associated with the biodistribution and specificity of the imaging agents.  GLP-
1 and exendin represent some common pharmacokinetic problems associated with using 
large peptides as targeting entities.  Therefore, it is beneficial to develop a new class of 
peptide-based imaging agents for the GLP-1R that are not based on the structure of the 
endogenous ligands and have a significantly reduced size.  The development of 
organometallic OBOC peptide libraries provides a potential method to overcome the 
limitations associated with endogenous ligand scaffolds in discovering small peptide 
molecules with high affinity. 
The nature of the active site of the GLP-1R requires interactions between the 
ligand and the receptor at a variety of spatially distant points.  This results in the GLP-1 
having a large number of amino acids that are considered necessary for binding and that 
are located through the entire backbone of the peptide hormone.  As such, it is unlikely 
that small peptide-based imaging agents will interact with the active site.  Therefore, the 
library screening of small peptides might result in allosteric interactions between the 
ligand and the target.  Family B of the GPCR superfamily, of which GLP-1R is a part, 
has been shown to be resistant to the development of compounds showing allosteric 
interactions.
112
  There are few reports of compounds showing allosteric interactions with 
the GLP-1R, all of which are small molecules (Figure 4.2) 
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Figure 4.2  Allosteric small molecule antagonists of the GLP-1R. 
 
The first molecule, T-0632, discovered to allosterically block peptide activity at 
the GLP-1R was reported in 2001.
113
  The compound has an observed IC50 = 1.2 µm ± 
0.4 µm.  6,7-dichloro-2-methylsulfonyl-3-N-tert-butylamino quinoxaline and Quecetin 
were investigated in 2010,
114
 the former was previously found to be an allosteric 
modulator with a binding affinity of 0.1 µm ± 0.2 µm.
115
  Their binding properties were 
investigated and found that they interact differently with the GLP-1R as they do not 
produce the same effects on cell pathways such as cAMP signal pathway stimulation and 
intracellular Ca
2+
 levels. 
The binding interactions of these small molecule inhibitors are not well 
understood as the binding mechanism and binding site are not known.  Nevertheless, 
these few compounds demonstrate the ability to discover compounds which can interact 
with GLP-1R in an allosteric fashion.  Fortunately, knowledge of allosteric binding 
interactions is not a prerequisite to developing allosteric-based imaging agents.  As long 
as a potential imaging agent binds to the GLP-1R with high binding affinity and 
specificity, the particular binding interactions do not necessarily need to be fully 
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understood, because imaging agents are introduced to the body in small quantities in 
comparison to therapeutic pharmaceuticals.  Therefore, the affect of the binding of the 
imaging agent on the signalling pathway cascades are negligible. 
The development of allosteric GLP-1R imaging agents provides means to 
overcome the difficulty of utilizing the scaffolds of GLP-1 and exendin.  These large 
peptides have poor pharmacokinetic properties; comparatively, small peptides, do not 
have these problems, in general.  Because of the properties of the GLP-1R binding site, 
small peptides would be expected to interact through allosteric means.  Therefore, the use 
of organometallic OBOC peptide libraries can be utilized to discover small peptides that 
interact with the GLP-1R. 
 
4.2 Results and Discussion 
4.2.1 Single bead MALDI Tandem Mass Spectrometry 
 
The use of tandem time-of-flight mass spectrometry to sequence rhenium(I) 
tricarbonyl-containing peptides that were previously synthesized and purified in bulk 
quantities, has been shown to be an effective method for amino acid determination.  
However, these conditions are not indicative of the methods used in OBOC screening.  
Different resin, different cleavage techniques, lower quantities and lack of purification 
are all conditions of OBOC library screening that need to be addressed.  Therefore, the 
first step in creating an organometallic OBOC peptide library is to verify the ability to 
sequence OBOC beads under library screening conditions. 
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The use of tentagel S NH2 resin is necessary for OBOC peptide libraries.  The 
difference between Rink Amide and tentagel resin is based on the functional groups to 
which the peptides are attached.  Tentagel contains a free amine, and as such forms an 
amide bond when peptides are attached.  Therefore, the acidic cleavage conditions which 
remove side-chain protecting groups, do not remove the peptide from the resin.  This is 
important because the peptides need to be deprotected but still remain on the resin in 
order to be screened against GLP-1R.  Then, in order to sequence the peptide through 
MALDI MS/MS, the peptide needs to be cleaved through the use of an ANP (2-amino-3-
(2-nitrophenyl)propanoic acid) photolinker (Scheme 4.1). 
 
 
Scheme 4.1  The synthesis of compound 3.2 on tentagel S NH2 resin with a UV cleavable 
ANP photolinker.  The organometallic peptide was cleaved from a single bead. 
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First the Fmoc-ANP photolinker was added to the resin under standard coupling 
conditions, and subsequently deprotected.  In the absence of light, Fmoc-amino acids 
were added sequentially resulting in the peptide H-QATDKFTF.  The organometallic was 
added under standard conditions.  TFA/scavengers are then used to deprotect the side-
chains of the amino acids with the peptide remaining on the resin.  This was verified by 
the lack of observable peptide in the TFA/scavengers solution after three hours of side-
chain cleavage.  Subsequently, under a fluorescence microscope, a single bead was 
selected and placed in approximately 50 µL of water and cleaved through the use of UV 
light for three hours, resulting in a dilute solution of organometallic peptide.  These 
conditions are identical to the conditions that an OBOC library would be screened.  This 
produces a solution of compound 3.2 that is mixed with a CHCA solution and MALDI 
tandem mass spectrometry is then used to sequence the peptide.  The resultant tandem 
mass spectrum is compared to the bulk-purified peptide results (Figure 4.3) 
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Figure 4.3  A comparison of the product ion spectra of compound 3.2 obtained by 
MALDI TOF/TOF mass spectrometry.  a)  The spectrum of the HPLC purified 
organometallic peptide.  b) The spectrum of the organometallic peptide cleaved from a 
single 90 µm tentagel bead under OBOC screening conditions.  The spectra are very 
similar and contain identical peaks. 
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The product ion mass spectrum obtained is almost identical to the purified peptide 
spectrum.  All of the same peaks are present in the single-bead spectrum and the HPLC 
purified spectrum.  This provides good evidence for the applicability of MALDI tandem 
mass spectrometry to organometallic OBOC peptide library screening. 
 
4.2.2 Organometallic OBOC Peptide Library Synthesis 
 
Because of the success of sequencing an organometallic peptide from a single 
tentagel bead with an ANP linker, a library of Re(CO)3-PADA organometallic peptides 
was created to be screened against the GLP-1R.  All natural amino acids were used, 
except cysteine, methionine and isoleucine.  Cysteine forms disulfide bonds between 
peptide chains that would result in difficulty in sequencing procedures.  Methionine is not 
stable to UV cleavage conditions and is prone to oxidation.  Isoleucine is isobaric with 
leucine and they cannot be distinguished from each other by mass spectrometry.  
Therefore, seventeen amino acids are used to create peptides with eight amino acids.  
This results in a library of almost seven billion (17
8
) possible peptide sequences.  
However, in order to create a library with that many peptide sequences, kilograms of 
resin would be required; this is neither economical nor practical.  Only 1 g of beads is 
used in the library resulting in approximately 1.5 million unique peptide sequences. 
Beads are coupled to Fmoc-ANP-OH and subsequently separated into 17 different 
wells, each corresponding to a different amino acid.  Using an automatic peptide 
synthesizer, each bead is deprotected and a unique peptide is added to each well.  The 
beads from each well are then recombined, mixed together, and then split back into the 
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wells.  This iterative cycle is repeated eight times until a library of beads, each with a 
unique peptide sequence, was created.  Initially, utilizing three equivalents of amino acid, 
the peptide coupling was observed to be incomplete, resulting in the observation of 
multiple different peptides present on a single bead.  Increasing the proportion of amino 
acids to five equivalents, as well as the coupling time, resulted in complete coupling as 
observed by mass spectrometry.  The beads are then recombined and then the Re(CO)3-
PADA complex is added to the N-terminus of the peptide.  Four equivalents of the 
rhenium(I) tricarbonyl complex are coupled per peptide chain, resulting in complete 
conversion.  Five millilitres of a mixture of TFA/H2O/TIS was added to the beads in 
order to remove the side-chain protecting groups of the amino acids.  The purity of the 
library is accessed through MALDI mass spectrometry, in which only one compound is 
observed for each single bead.  The resultant beads contain a unique organometallic 
peptide connected to the bead through an ANP photolinker.  The organometallic peptide 
contains no protecting groups and can be screened against the GLP-1R target. 
 
4.2.3 Single Bead Organometallic OBOC Peptide Deconvolution 
 
Single beads from the library were selected from the library in order to determine 
the ability of MALDI MS/MS to sequence unknown organometallic octapeptides.  
Previously, rhenium(I) tricarbonyl peptide sequences have been sequenced through this 
method, however the identity of the peptide is already known.  The de novo sequencing 
of unknown organometallic peptides is significantly more difficult in comparison because 
peaks cannot be expected to be present.  As such, single beads from the library were 
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individually selected via the use of a fluorescence microscope.  Then, beads were 
irradiated with UV light for three hours in approximately 50 µL of water.  The resultant 
organometallic peptide sequences were co-crystallized with CHCA and MALDI tandem 
spectra were obtained and sequenced (Table 4.1). 
Table 4.1  Deconvoluted PADA-Re(CO)3 peptides from an organometallic OBOC 
peptide library sequenced through manual de novo methods. 
Compound Deconvoluted Organometallic Peptide 
Sequence 
Calculated 
Mass (m/z) 
Observed 
Mass (m/z) 
4.1 [PADA-Re(CO)3]-VLYGVRPV-NH2 1335.51 1335.49 
4.2 [PADA-Re(CO)3]-ALHEVGSW-NH2 1373.46 1373.43 
4.3 [PADA-Re(CO)3]-HNES(K/Q)EGT-NH2 1376.38 1376.43 
4.4 [PADA-Re(CO)3]-FEGGEESY-NH2 1392.40 1392.37 
4.5 [PADA-Re(CO)3]-YARES(K/Q)AD-NH2 1414.47 1414.45 
4.6 [PADA-Re(CO)3]-DHHLRAYV-NH2 1443.48 1443.46 
4.7 [PADA-Re(CO)3]-TEHNP(K/Q)HE-NH2 1466.44 1466.48 
 
The observed organometallic peptides all contain eight amino acids, consistent 
with the library properties.  The ability to sequence these peptides was aided by the 
rhenium isotopic signature present on N-terminal fragments, allowing the ability to 
distinguish between N and C-terminal fragments.  Furthermore, the mass of the Re(CO)3-
PADA chelate is known and facilitates the sequencing by starting de novo sequencing at 
a universal m/z value.  In addition, from the precursor spectrum, the total mass was also 
known.  The resultant table of peptides shows calculated and observed mass in close 
agreement (Table 4.1).  Lysine and glutamine are almost isobaric and therefore cannot be 
distinguished in mass spectrometry.  Like Re(CO)3-PADA-QATDKFTF-NH2, (3.2), the 
most intense peak in almost all of the deconvoluted organometallic peptide sequences, 
with the exception of 4.5, was the b1 fragment, suggesting that this fragmentation pattern 
is in general the most favourable pathway for N-terminal PADA rhenium(I) tricarbonyl 
99 
 
 
 
chelates.  Approximately 50% of beads sequenced by MALDI MS/MS resulted in 
complete assignments of amino acids.  Many of the incomplete fragmentation patterns 
resulted in the majority of amino acids being assigned, with the omission of two amino 
acid identities.  Despite the fact that not all of the peptide sequences could be identified, a 
fifty percent success rate is acceptable because the purpose of screening is to identify 
bioactive peptides and not to infer about structure-activity relationships. 
 
4.2.4 Organometallic OBOC Peptide Library Screening Against the GLP-1R 
 
In order to find bioactive peptide sequences that target the GLP-1R from the 
organometallic OBOC peptide library, fluorescent CHO (Chinese hamster ovarian) cells 
over-expressing the GLP-1R were created.  These cells were then incubated with the 
OBOC library and the beads containing the bioactive organometallic peptide sequences 
had cells attached to them.  In order to facilitate high throughput screening, after 
incubation, the beads are sorted utilizing a COPAS biosorter.  The biosorter flows beads 
and lasers are used to measure the fluorescence, the size of the particle and the extinction 
(the amount of light which is blocked by the particle).  The beads that have cells bound to 
them have a larger size and higher fluorescence.  In this way, beads that have bioactive 
peptides can be separated from beads which do not have bioactive peptides due to the 
lack of peptide-cell interaction on the latter. 
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Figure 4.4  The procedure for screen an OBOC peptide library against cells.  This 
technique accounts for non-specific binding interactions. 
 
The process of screening an organometallic OBOC peptide library against the 
GLP-1R begins with the incubation of the library with CHO cells expressing the GFP 
(green fluorescent protein).  These cells are green fluorescent and are used as a control to 
account for non-specific binding in the peptide library.  Peptide sequences would be 
expected to interact with some of the thousands of biomolecules expressed on a cells’ 
surface, and as such if the organometallic peptide sequences interact with these 
biomolecules they produce false positive results (Figure 4.5).   
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Figure 4.5  Organometallic OBOC peptide library after incubation with GFP expressing 
cells.  There are a number of beads circled in white that show interaction with the cells 
while most do not.  The intensity of the auto-fluorescence of the tentagel beads varies 
from bead to bead. 
 
In order to account for these interactions, the incubation of the organometallic 
OBOC peptide library with CHO cells allows for the removal of the peptides showing 
these interactions.  The beads that did not show interaction with the control green CHO 
cells were then incubated with red GLP-1R over-expressing CHO cells. 
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Figure 4.6  A diagram of CHO cells showing green and red fluorescence.  The green 
cells express GFP (green fluorescent protein) and act a control for non-specific binding.  
The red cells express tdTomato and overexpress the GLP-1R. 
 
The organometallic OBOC peptide library (1.5 million beads) was incubated with 
approximately 10 million CHO control cells suspended in 10 mL of PBS for one hour 
being mixed at 300 rpm at 37 
o
C.  After incubation, formaldehyde was added to the 
solution in order to attach the cells to the beads permanently.  The formaldehyde reacts 
with the biomolecules present on cell surface in order to create cross-linking.  The beads 
were then rinsed with PBS three times in order to remove any of the unbound cells.  The 
beads were then sorted via the COPAS biosorter.  From the results, two distinct 
populations of the beads are shown in the library, the more fluorescent population contain 
control cells bound to the beads (Figure 4.7). 
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Figure 4.7  A graph from the COPAS biosorter showing two distinct populations of 
beads after incubation with green control cells.  The y-axis is a measurement of green 
fluorescence and the x-axis is the time-of-flight or size.  The top population shows 
increased fluorescence and contains GFP CHO cells with non-specific binding 
interactions.  The bottom population contains no cells. 
 
The population containing smaller, less fluorescent beads have not interacted with 
cells.  After isolating these populations, investigation of the beads under a fluorescent 
microscope revealed that most of the bottom population have no cells bound to them and 
most of the more fluorescent population contain cell-bead interactions (Figure 4.8). 
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Figure 4.8  Tentagel bead interacting with three visible GFP expressing cells. 
 
After the non-interacting bead population was isolated, the beads were incubated 
with red GLP-1R over-expressing cells utilizing the same procedure as outlined above.  
The biosorter was once again used to separate two populations of beads, those showing 
and not showing interactions with the GLP-1R.  In this case, the beads showing 
interactions with the cells were to be isolated to find peptide sequences interacting with 
the GLP-1R.  However, there were problems associated with bead sorting based on red 
fluorescence on the COPAS biosorter that could not be overcome to produce conditions 
to find two separate populations.  The auto-fluorescence of the beads in the red is not as 
uniform as it is in green, and the variation in red fluorescence masks the bioactive beads. 
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Figure 4.9  A graph from the COPAS biosorter with the y-axis is a measurement of red 
fluorescence and the x-axis is time-of-flight or size.  This graph illustrates that there are 
not two distinct populations of beads containing red cells and those without. 
 
Therefore, because of the difficulties associated with screening red fluorescence, 
manual separation under a fluorescence microscope was utilized.  The beads were 
isolated from each other via the identification of red cells bound to beads and picking the 
beads out with a pipette.  This process is time consuming, technically challenging and not 
inherently high throughput.  Approximately 20 beads were isolated via this method.  The 
organometallic peptides were cleaved from resin utilizing a UV light for three hours and 
MALDI was subsequently preformed on the resultant solution. 
 
4.2.5 MALDI TOF/TOF Deconvolution of “Hit” Library Beads 
 
The MALDI tandem mass spectrometry results of the 20 beads produced mass 
spectra with minimal signals.  Most of the beads showed no signal in the corresponding 
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mass spectrum.  It is suspected that the time-consuming isolation of beads under the 
fluorescent microscope resulted in the cleavage of much of the organometallic peptides 
from the resin.  Light is shone on the beads in order to induce fluorescence, the ANP 
photolinker was cleaved and peptide removed from resin.  Unfortunately, out of the 20 
isolated beads, only two produce a precursor ion spectrum.  Of these two peptide hits, 
only one of their corresponding product ion spectra could be fully deconvoluted via de 
novo sequencing.  The organometallic peptide was identified as Re(CO)3-PADA-
RVTH(K/Q)(K/Q)(K/Q)E-NH2 (4.8) through the use of b ion fragments (Figure 4.10). 
 
Figure 4.10  The product ion spectrum of the organometallic octapeptide 4.8 showing the 
b series fragments. 
 
The product ion spectrum of compound 4.8 shows similar properties to the 
previously investigated Re(CO)3-PADA organometallic peptides.  The b1 fragment is by 
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far the most intense, as was the case with every previous Re(CO)3-PADA peptide except 
for compound 4.5.  The compound contains three positions which have been assigned 
either lysine or glutamine.  As such, the actual identity of the peptide is one of eight 
possible peptides. 
Table 4.2  Fragment assignments from series b of the product ion spectrum of compound 
4.8.  The masses of the b8 ion can be determined because of the known mass of the 
peptide and the N-terminal chelate.  [M+H]
+ 
m/z = 1497.52 (rhenium-185 peak). 
Label Fragment Peak 
(m/z) 
Difference 
between 
peaks 
(m/z) 
Amino Acid 
Assignment 
b0 RE-PADA-NH3 492.0   
b1 RE-PADA-R 631.1 156.1 Arginine 
b2 RE-PADA-RV 730.2 99.1 Valine 
b3 RE-PADA-RVT 831.3 101.1 Threonine 
b4 RE-PADA-RVTH 968.3 137.1 Histidine 
b5 RE-PADA-RVTH(K/Q) 1096.4 128.1 Lysine/Glutamine 
b6 RE-PADA-RVTH(K/Q)(K/Q) 1224.4 128.0 Lysine/Glutamine 
b7 RE-PADA-
RVTH(K/Q)(K/Q)(K/Q) 1352.5 128.1 Lysine/Glutamine 
b8 NOT OBSERVED 1481.5 129.0 Glutamic Acid 
 
The other peptide “hit” was partially sequenced via de novo methods.  The 
identity of the peptide sequence is Re(CO)3-PADA-SWGxxLFS-NH2 (4.9).  The b1 
fragment is again the most intense peak in the spectrum (Figure 4.11).  Two positions 
could not be identified due to lack of fragmentation at that position. 
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Figure 4.11  The product ion spectrum of the organometallic octapeptide 4.9 showing the 
b series fragments. 
 
The mass allotted to the unknown dipeptide (xx) is approximately m/z 184.  Based 
on the known masses of amino acids, the identity of these two amino acids could be 
either a combination of proline and serine or alanine and leucine.  Additionally, the order 
of the two amino acids is not known.  This highlights the limitations associated with de 
novo sequencing.  Despite the fact that eight of nine b series fragments were determined, 
the identity of the peptide sequence could only be narrowed down to four potential 
sequences. 
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Table 4.3  Fragment assignments from series b and y of the product ion spectrum of 
compound 4.9.  The masses of the b8 ion can be determined because of the known mass 
of the peptide and the N-terminal chelate.  [M+H]
+ 
m/z = 1353.48 (rhenium-185 peak). 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks 
(m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-S 562.0 87.0 Serine 
b2 RE-PADA-SW 748.1 186.1 Tryptophan 
b3 RE-PADA-SWG 805.1 57.0 Glycine 
b4 RE-PADA-SWGx    
b5 RE-PADA-SWGxx 989.3   
b6 RE-PADA-SWGxxL 1102.3 113.1 Leucine 
b7 RE-PADA-SWGxxLF 1249.4 147.1 Phenylalanine 
b8 NOT OBSERVED 1336.4 87.0 Serine 
 
From the information given by the two organometallic peptide sequences, the two 
sequences do not appear to be similar.  Compound 4.8 is a very positively charged 
peptide species, containing an arginine, histidine and potentially as many as three lysine 
residues, all of which are capable of holding a positive charge.  Conversely, 4.9 is a 
largely hydrophobic peptide sequence containing phenylalanine, leucine, glycine and 
tryptophan with hydroxyl group of serine being the only polar functionality within the 
organometallic peptide.  Therefore, it is difficult to draw any conclusions about the 
binding properties of organometallic octapeptides.  In order to determine patterns among 
this class of bioactive molecule a larger sample of peptide “hit” sequences is necessary.  
Furthermore, compounds 4.8 and 4.9 need to be evaluated in solution phase in order to  
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determine their quantitative binding affinities in order to determine their true ability to 
interact with GLP-1R. 
From the information given by the two organometallic peptide sequences, the two 
sequences do not appear to be similar.  Compound 4.8 is a very positively charged 
peptide species, containing an arginine, histidine and potentially as many as three lysine 
residues, all of which are capable of holding a positive charge.  Conversely, 4.9 is a 
largely hydrophobic peptide sequence containing phenylalanine, leucine, glycine and 
tryptophan with hydroxyl group of serine being the only polar functionality within the 
organometallic peptide.  Therefore, it is difficult to draw any conclusions about the 
binding properties of organometallic octapeptides.  In order to determine patterns among 
this class of bioactive molecule a larger sample of peptide “hit” sequences is necessary.  
Furthermore, compounds 4.8 and 4.9 need to be evaluated in solution phase in order to 
determine their quantitative binding affinities in order to determine their true ability to 
interact with GLP-1R. 
 
4.3 Conclusions 
 
In this chapter, an organometallic OBOC peptide library was synthesized 
containing octapeptides with an N-terminal PADA-rhenium(I) tricarbonyl complex.  
Random beads from the library were selected and MALDI tandem mass spectrometry 
was used to determine the identity of the peptide sequences on the bead.  A fifty percent 
success rate was obtained in the sequencing of the unknown peptide sequences.  These 
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results have demonstrated that rhenium(I) tricarbonyl-containing peptide sequences can 
be deconvoluted using MALDI tandem mass spectrometry. 
The library was then screened against cells over-expressing the GLP-1R in order 
to identify bioactive organometallic peptide sequences.  Two such peptide sequences 
were identified, although the use of a fluorescence microscope was resorted to as a 
method to identify fluorescent beads due to failure to find proper sorting conditions for 
red cells.  This is the first reported example of an organometallic OBOC peptide library 
screened against a biological target for bioactive molecules.  Two such sequences are not 
enough data to determine patterns and infer relationships between the structure of the 
ligand and its correlation with the binding affinity.  These sequences need to be further 
evaluated in solution phase to determine their quantitative binding affinity. 
 
4.4 Experimental 
4.4.1 General Procedures 
 
All chemicals and solvents were purchased from commercially available sources 
and used without further purification.  Coupling agents, resin and Fmoc amino acids were 
purchased from Peptides International (Louisville, KY) or Aapptec (Louisville, KY).  
Solvents and other chemicals were purchased from Fisher Scientific and Sigma Aldrich.  
Automated peptide synthesis was done using an Advanced ChemTech Apex Multiple 
Peptide Synthesizer.  Bead sorting was accomplished using a Union Biometrica COPAS 
BIOSORT instrument.  Fluorescence was investigated using a fluorescence microscope.  
MALDI mass spectrometry experiments were done utilizing an Applied Biosystems 4700 
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PDS.  This instrument is equipped with an Nd: YAG laser tuned to a wavelength of 355 
nm, with a 200 Hz laser rate operating in reflectron mode and tandem time-of-flight ion 
detectors in series.  The mass spectrometer was calibrated with a mixture of angiotensin I 
(m/z 1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da. 
 
4.4.2 Single Bead Organometallic Peptide Synthesis 
 
Re(CO)3-QATDKFTF-NH2 (3.2) 
The peptide synthesis was carried out on tentagel S NH2 resin (0.1 mmol) and 
using standard Fmoc peptide synthesis.  Fmoc-ANP-OH (0.4 mmol, 4 eq.) was dissolved 
in DMF (1mL) and combined with HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8 
eq.).  The mixture was agitated for three hours and the process repeated once.  The 
peptide was then deprotected using 20% piperidine in DMF (v/v) and the amino acids 
were coupled sequentially.  2.7 (0.4 mmol, 4 eq.) was dissolved in DMF (2 mL) with 
HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8 eq.) and mixed with peptide 
containing the resin.  The resin and solution were agitated overnight and subsequently 
washed with DMF and DCM resulting in the desired organometallic peptide.  The 
organometallic peptide was cleaved from resin by selecting a single bead under a 
fluorescence microscope and irradiated with UV light for three hours in 50 µL of water.  
The solution was then sequenced via MALDI TOF/TOF. 
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4.4.3 OBOC Library Synthesis 
 
OBOC peptide libraries were synthesizer utilizing the Advanced ChemTech 
Multiple Peptide Synthesizer.  The libraries were created with the seventeen natural 
amino acids with the exclusion of methionine, cysteine and isoleucine.  Tentagel S NH2 
resin (1.30 g, 0.33 mmol) with a loading of 0.26 mmol/g.  Fmoc-ANP-OH (1.42 g, 3.30 
mmol, 10 eq.) was coupled to the resin using standard double coupling Fmoc peptide 
synthesis procedures.  The resin was then kept in the dark for the rest of the procedure.  
The resin was divided into seventeen equal portions (0.07 g, 0.02 mmol) and placed in a 
single well.  The Fmoc was removed using 20% piperidine in DMF (v/v) (800 µL/well) 
repeated twice and to each well a different amino acid (0.10 mmol, 5 eq.) was coupled 
using HCTU (0.04 g, 0.10 mmol, 5 eq.) and DIPEA (0.035 mL, 0.20 mmol, 10 eq.) in 
DMF (2.4 mL), rinsed and repeated.  The resin was rinsed in DCM and recombined in a 
beaker.  The resin was mixed thoroughly and divided into seventeen equal portions and 
placed back in the wells.  The process of deprotection and coupling of amino acids was 
repeated seven more times creating a library of octapeptides.  The resin was removed 
from the wells, the Fmoc was removed and coupled with compound 2.7,  Re(CO)3-PADA 
(0.51 g, 1.0 mmol, 3 eq.), HCTU (0.41 g, 1.0 mmol, 3 eq) and DIPEA (0.350 mL, 2.0 
mmol, 6 eq.)  in DMF overnight.  This results in an organometallic Re(CO)3-PADA 
octapeptide OBOC library.  The purity of the library was verified by MALDI MS. 
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4.4.4 Cell Growth 
 
The CHO-GLP-1R/tdtomato cells were grown in F-12K media/10% FBS plus 200 µg/ml 
G418 and 1 mg/mL hygromycin in order to maintain the stable expression of GLP-1R 
and tdtomato, respectively. The CHO-EGFP cells were grown in F-12K media/10% FBS 
plus 1 mg/mL G418 in order to maintain stable EGFP expression. 
 
4.4.5 Library Incubation 
 
The library was washed with dichloromethane, methanol and three times with 
aqueous PBS (phosphate buffered saline).  The cells were dissociated with 2 mM EDTA, 
collected, spun down and then resuspended in HBSS (Hank's buffered saline solution) at 
density of 2 x 10
6
 cells/mL.  20 x 10
6
 cells were plated in a 10 cm Petri dish and the 
beads (approximately 1.5 million beads) were added to the dish. The dish was agitated at 
70 rpm for 1 hour, in a humidified 37 
o
C incubator. Paraformaldehyde was added to the 
dish to a final concentration of 4 % and incubated at room temperature for 10 minutes 
and placed in a 40 mL falcon tube.  The beads settled at the bottom and the cell-bead 
pellet was washed twice with PBS. 
 
4.4.6 Library Screening 
 
The library, having previously been incubated with CHO cells, was screened 
using a Union Biometrica COPAS biosorter.  The library was suspended in PBS solution 
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and mixed thoroughly.  The biosorter measured the size and green fluorescence and 
separated the beads into two populations, one with fluorescent cells and one without.  
This was verified by investigation under the fluorescence microscope.  The population 
without the cells was washed with methanol and PBS.  The population was then 
incubated again with CHO cells over-expressing the GLP-1R and expressing the red 
fluorescent protein tdTomato.  The incubation proceeded through an identical method 
outlined above.  An inverted fluorescent microscope was used to separate the beads 
containing red fluorescent cells. 
 
4.4.7 MALDI Tandem Mass Spectrometry 
 
Beads were isolated via use of a fluorescent microscope and the beads were 
placed in 50 µL of water and then irradiated with UV light for three hours.  An aliquot of 
the organometallic peptide solution (2 µL) and a CHCA solution (2 µL) were mixed for a 
few minutes.  CHCA solution is a mixture of 50:50 water/acetonitrile (v/v) with the 
addition of 0.1% TFA at a concentration of 5 mg/mL.  A portion of the mixture (0.7 µL) 
was then spotted onto a MALDI plate in duplicate for analysis.  The solvent in the 
mixture was allowed to evaporate resulting in the co-crystallization of the matrix and 
peptide.  The samples were then analyzed via MALDI tandem mass spectrometry.  The 
precursor ion spectra show rhenium 185/187 isotopic distributions.  The rhenium-185 
peak was chosen for fragmentation via collision-induced dissociation with argon gas.  
Tandem mass spectra were obtained and peaks assigned via manual de novo analysis. 
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Chapter 5:  Conclusions 
 
 Molecular imaging has become an important part of modern medicine due to its 
ability to obtain information assisting in diagnosis in a non-invasive manner.
1
  The 
development of new nuclear imaging technology relies on developments from a wide 
variety of scientific and medical fields; the production and accessibility of radioisotopes, 
knowledge of potential biological targets and the development of new imaging agents, 
among many others, are all important in furthering the applicability and use of nuclear 
medicine. 
 The research in this dissertation utilizes OBOC (one-bead, one-compound) 
combinatorial peptide libraries to further the development of imaging agents by the 
incorporation of organometallic coordination compounds into the library.  Synthesis of 
rhenium(I) tricarbonyl chelates as non-radioactive surrogates for technetium-99m, the 
most widely used medical radioisotope, is discussed as well as the incorporation of the 
chelates into peptide backbones.  The ability to sequence rhenium(I) tricarbonyl-
containing peptides through MALDI tandem mass spectrometry has been successful for 
all chelates investigated.  Furthermore, an organometallic OBOC peptide library was 
applied to the discovery of new GLP-1R (glucagon-like peptide 1 receptor) candidate 
imaging agents for diabetes and insulinomas. 
 Four rhenium(I) tricarbonyl chelates have been synthesized, PADA, BPA, NTA 
and PHA, and were attached directly to the N-terminus of a peptide chain.  These chelates 
were chosen because they provide a good representation of the variety of chelates 
associated with the rhenium(I) tricarbonyl metal centre.  Re(CO)3-PADA, is known to be 
117 
 
 
 
a stable chelate
52
 that forms neutral complexes.  Re(CO)3-BPA and Re(CO)3-NTA 
provides positively and negatively charged coordination compounds, while Re(CO)3-
PHA is a novel chelation system holding a neutral charge.  An investigation into the 
ability to identify unknown organometallic amino acid sequences through the use of 
MALDI tandem mass spectrometry has been accomplished.  The results of this study into 
organometallic peptide fragmentation patterns lead to the conclusion that a wide variety 
of peptide chelation systems can be successfully incorporated on the N-terminus of the 
peptide and these chains can be sequenced by MALDI TOF/TOF.  All rhenium(I) 
tricarbonyl peptides were successfully sequenced by tandem mass spectrometry.  
Re(CO)3-PADA and Re(CO)3-BPA peptides provide intense and easily identifiable 
amino acid fragments.  The fragmentation pattern of the Re(CO)3-NTA peptide does not 
have complete fragmentation series, however was still successfully sequenced.  The 
Re(CO)3-PHA peptide is the first known example of a phenol based rhenium(I) 
tricarbonyl chelate bound to an amino acid chain.  The fragmentation pattern of the 
Re(CO)3-PHA peptide compound allowed for the successful identification of the peptide 
sequence, as well as the unique observation of the fragmentation of the PHA chelate 
resulting in the neutral loss of orthoquinone methides.  The results of the MALDI 
TOF/TOF sequencing experiments indicate that a wide variety of rhenium(I) tricarbonyl 
chelates can be identified in this manner. 
 An N-terminal Re(CO)3-PADA OBOC peptide library was synthesized containing 
approximately 1.5 million unique peptide sequences utilizing all natural amino acids with 
the exception of cystiene, isoleucine and methionine.  The library was screened against 
fluorescent CHO (Chinese hamster ovarian) cells over-expressing the GLP-1 receptor in 
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order to identify imaging agent candidates for use in diabetes or insulinoma diagnosis and 
monitoring.  Two organometallic peptide sequences, Re(CO)3-PADA-
RVTH(K/Q)(K/Q)(K/Q)E-NH2 and Re(CO)3-PADA-SWGxxLFS-NH2, were isolated 
from the library and identified by tandem mass spectrometry.  Cells were attached to the 
beads that contained these two organometallic peptides.  Because only two “hit” 
sequences were isolated, inferences into the structure-activity relationships cannot be 
conclusively made. 
 Recent developments of OBOC peptide libraries have focused on the 
incorporation of unnatural and non-peptide-like structures into combinatorial libraries.  
OBOC libraries are robust to a wide variety of chemistry, which is one of their main 
advantages in comparison to other combinatorial libraries.  Additions of unnatural amino 
acids
97
 and quaternary ammonium salts
98
 have been recently reported.  Moreover, OBOC 
peptoid (N-substituted oligo-glycines)  libraries
96
 have been developed.  Additionally, the 
identification of peptoid structures through tandem mass spectrometry has also been 
shown.  Non-natural peptide-like structures are generally more stable to in vivo 
conditions, which is an important property of pharmaceuticals and imaging agents.  The 
research in this dissertation utilizes the same benefits of OBOC libraries to further utilize 
non-peptide structures to improve the development of nuclear imaging agents.  
Rhenium(I) tricarbonyl-containing OBOC peptide libraries have unnatural radionuclide 
surrogates in order to account for their influence on receptor binding affinity.  This 
advance in molecular imaging has the ability to alter the way in which peptide-based 
imaging agents are developed.  For the discovery of novel imaging agents, the 
organometallic OBOC peptide methodology outlined in this dissertation is superior to the 
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traditional OBOC approach.  Furthermore, organometallic OBOC peptide libraries could 
be used to investigate the influence of a large number of different imaging entity 
surrogates on known bioactive peptides. 
 In conclusion, novel organometallic OBOC peptide libraries have been 
synthesized through standard peptide chemistry, MALDI tandem mass spectrometry has 
been identified as a useful technique to deconvolute organometallic peptide sequences 
and a Re(CO)3-PADA peptide library has been used to identify potential imaging agents  
for the GLP-1R.  This technique has the potential to be applied to any number of 
radionuclide surrogates.  However, fragmentation patterns and chelate stability under 
fragmentation conditions would need to be investigated.  Organometallic OBOC peptide 
libraries provide a new methodology to expedite and economize the process of peptide-
based imaging agent discovery.  
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APPENDIX I – CHAPTER 2 
1
H NMR and 
13
C NMR spectra of 2.3 
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H NMR spectrum of 2.4 
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H NMR spectrum of 2.5 
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C NMR spectra of 2.7 
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C NMR spectra of 2.10 
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C NMR spectra of 2.11 
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C NMR spectra of 2.12a 
 
 
139 
 
 
 
 
1
H NMR spectrum of 2.12b 
 
1
H NMR spectrum of 2.12c 
  
140 
 
 
 
1
H NMR and 
13
C NMR spectra of 2.13 
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C NMR spectra of 2.14 
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APPENDIX II – Chapter 3 
HPLC trace and ES+ mass spectrum of 3.2 
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HPLC trace and ES+ mass spectrum of 3.3 
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HPLC trace and ES+ mass spectrum of 3.4 
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HPLC trace and ES+ mass spectrum of 3.6 
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APENDIX III – Chapter 4 
 
For all organometallic peptide product ion spectra, the rhenium-185 was selected for 
fragmentation 
The MS/MS spectrum of compound [PADA-Re(CO)3]-VLYGVRPV-NH2 (4.1) and b 
series peak assignments 
[M+H]
+
 calc: 1335.51, obs: 1335.49 (rhenium-187 peak) 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-V 574.1 99.1 Valine 
b2 RE-PADA-VL 687.2 113.1 Leucine 
b3 RE-PADA-VLY 850.2 163.0 Tyrosine 
b4 RE-PADA-VLYG 907.3 57.1 Glycine 
b5 RE-PADA-VLYGV 1006.3 99.0 Valine 
b6 
RE-PADA-
VLYGVR 1120.3 114.0 Asparginine 
b7 
RE-PADA-
VLYGVRP 1217.4 97.1 Proline 
b8 NOT OBSERVED 1316.5 99.0 Valine 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-ALHEVGSW-NH2 (4.2) and b 
series peak assignments 
[M+H]
+
 calc: 1373.46, obs: 1373.43 (rhenium-187 peak) 
Series Label Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-A 546.1 71.1 Alanine 
b2 RE-PADA-AL 659.1 113.0 Leucine 
b3 RE-PADA-ALH 796.2 137.1 Histidine 
b4 RE-PADA-ALHE 925.3 129.1 Glutamic Acid 
b5 RE-PADA-ALHEV 1024.3 99.0 Valine 
b6 RE-PADA-ALHEVG 1081.3 57.0 Glycine 
b7 
RE-PADA-
ALHEVGS 1168.3 87.0 Serine 
b8 NOT OBSERVED 1354.4 186.1 Tryptophan 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-HNES(K/Q)EGT-NH2 (4.3) and b 
series peak assignments 
[M+H]
+
 calc: 1376.38, obs: 1376.43 (rhenium-187 peak) 
Series Labe
l 
Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0     
b1 RE-PADA-H 612.1 137.01 Histidine 
b2 RE-PADA-HN 726.1 114 Asparginine 
b3 RE-PADA-HNE 855.2 129.1 Glutamic Acid 
b4 RE-PADA-HNES 942.2 87 Serine 
b5 RE-PADA-HNES(K/Q) 1070.3 128.1 Lysine/Glutamine 
b6 
RE-PADA-
HNES(K/Q)E 1199.3 129 Glutamic Acid 
b7 
RE-PADA-
HNES(K/Q)EG 1256.3 57 Glycine 
b8 NOT OBSERVED 1357.4 101.1 Threonine 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-FEGGEESY-NH2 (4.4) and b 
series peak assignments 
[M+H]
+
 calc: 1392.40, obs: 1392.37 (rhenium-187 peak) 
Series Labe
l 
Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0     
b1 RE-PADA-F 622.1 147.1 Phenylalanine 
b2 RE-PADA-FE 751.1 129 Glutamic Acid 
b3 RE-PADA-FEG 808.2 57.1 Glycine 
b4 RE-PADA-FEGG 865.2 57 Glycine 
b5 RE-PADA-FEGGE 994.2 129 Glutamic Acid 
b6 RE-PADA-FEGGEE 1123.2 129 Glutamic Acid 
b7 RE-PADA-FEGGEES 1210.3 87.1 Serine 
b8 NOT OBSERVED 1373.3 163 Tyrosine 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-YARES(K/Q)AD-NH2 (4.5) and 
b series peak assignments 
[M+H]
+
 calc: 1414.47, obs: 1414.45 (rhenium-187 peak) 
Series Labe
l 
Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-Y 638.1 163.1 Tyrosine 
b2 RE-PADA-YA 709.2 71.1 Alanine 
b3 RE-PADA-YAR 865.3 156.1 Arginine 
b4 RE-PADA-YARE 994.3 129.1 Glutamic Acid 
b5 RE-PADA-YARES 1081.2 86.9 Serine 
b6 
RE-PADA-
YARES(K/Q) 1209.4 128.1 Lysine/Glutamine 
b7 
RE-PADA-
YARES(K/Q)A 1280.4 71.1 Alanine 
b8 NOT OBSERVED 1395.4 115.0 Aspartic Acid 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-DHHLRAYV-NH2 (4.6) and b 
series peak assignments 
[M+H]
+
 calc: 1443.48, obs: 1443.46 (rhenium-187 peak) 
Series Labe
l 
Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-D 590.1 115.1 Aspartic Acid 
b2 RE-PADA-DH 727.1 137.1 Histidine 
b3 RE-PADA-DHH 864.6 137.5 Histidine 
b4 RE-PADA-DHHL 977.3 112.7 Leucine 
b5 RE-PADA-DHHLN 1091.3 114.0 Asparginine 
b6 RE-PADA-DHHLNA 1162.3 71.0 Alanine 
b7 RE-PADA-DHHLNAY 1325.5 163.1 Tyrosine 
b8 NOT OBSERVED 1424.4 99.0 Valine 
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The MS/MS spectrum of compound [PADA-Re(CO)3]-TEHNP(K/Q)HE-NH2 (4.7) and b 
series peak assignments 
[M+H]
+
 calc: 1466.44, obs: 1446.48 (rhenium-187 peak) 
Series Labe
l 
Fragment Peak 
(m/z) 
Difference 
between 
peaks (m/z) 
Amino Acid 
Assignment 
 
 
 
b 
series 
b0 NOT OBSERVED 475.0   
b1 RE-PADA-T 576.1 101.1 Threonine 
b2 RE-PADA-TE 705.2 129.1 Glutamic Acid 
b3 RE-PADA-TEH 843.2 137 Histidine 
b4 RE-PADA-TEHN 956.2 114 Asparginine 
b5 RE-PADA-TEHNP 1053.3 97.1 Proline 
b6 
RE-PADA-
TEHNP(K/Q) 1181.4 128.1 Lysine/Glutamine 
b7 
RE-PADA-
TEHNP(K/Q)H 1318.4 137 Histidine 
b8 NOT OBSERVED 1447.5 129.1 Glutamic Acid 
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